Sucampo Pharmaceuticals 10-Q 7 Nov 14 2014 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 31, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'Sucampo Pharmaceuticals, Inc.	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	44,349,465
Amendment Flag	'false	'
Entity Central Index Key	'0001365216	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Accelerated Filer	'
Entity Well-known Seasoned Issuer	'No	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$56,087	$44,102
Investments, current	8,857	16,003
Product royalties receivable	16,811	14,829
Unbilled accounts receivable	2	1
Accounts receivable, net	8,453	5,407
Prepaid and income taxes receivable	3,678	9
Deferred tax assets, current	'	2,028
Deferred charge, current	377	673
Restricted cash, current	26,114	26,115
Inventory	133	209
Prepaid expenses and other current assets	3,550	3,977
Total current assets	124,062	113,353
Investments, non-current	13,046	7,219
Property and equipment, net	882	1,156
Intangible assets, net	157	6,438
Deferred tax assets, non-current	1,436	1,212
Deferred charge, non-current	2,261	4,540
Restricted cash, non-current	2,313	2,471
Other assets	461	488
Total assets	144,618	136,877
Current liabilities:	'	'
Accounts payable	5,924	7,614
Accrued expenses	7,160	5,682
Deferred revenue, current	2,047	1,365
Income tax payable	'	701
Notes payable, current	26,342	26,892
Other current liabilities	2,436	358
Total current liabilities	43,909	42,612
Notes payable, non-current	21,741	25,828
Deferred revenue, non-current	5,457	6,169
Deferred tax liability, non-current	343	2,066
Other liabilities	1,512	1,233
Total liabilities	72,962	77,908
Preferred stock, $0.01 par value; 5,000,000 shares authorized at September 30, 2014 and December 31, 2013; no shares issued and outstanding at September 30, 2014 and December 31, 2013	0	0
Additional paid-in capital	80,897	72,109
Accumulated other comprehensive income	15,643	15,601
Treasury stock, at cost; 524,792 and 524,792 shares	-2,313	-2,313
Accumulated deficit	-23,014	-26,860
Total stockholders' equity	71,656	58,969
Total liabilities and stockholders' equity	144,618	136,877
Common Class A [Member]	'	'
Current liabilities:	'	'
Common stock value	443	432
Common Class B [Member]	'	'
Current liabilities:	'	'
Common stock value	$0	$0

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Preferred stock, par value (in Dollars per share)	$0.01	$0.01
Preferred stock,shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Treasury stock, shares	524,792	524,792
Common Class A [Member]	'	'
Common stock, par value (in Dollars per share)	$0.01	$0.01
Common stock, shares authorized	270,000,000	270,000,000
Common stock, shares issued	44,330,465	43,315,749
Common stock, shares outstanding	44,330,465	43,315,749
Common Class B [Member]	'	'
Common stock, par value (in Dollars per share)	$0.01	$0.01
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	0	0
Common stock, shares outstanding	0	0

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues:	'	'	'	'
Research and development revenue	$1,797	$2,027	$5,281	$16,288
Product royalty revenue	16,811	13,595	44,200	37,271
Product sales revenue	11,717	5,378	25,572	10,994
Co-promotion revenue	936	'	2,021	61
Contract and collaboration revenue	202	163	619	490
Total revenues	31,463	21,163	77,693	65,104
Costs and expenses:	'	'	'	'
Costs of goods sold	4,974	6,267	12,163	9,457
Intangible assets impairment	5,631	'	5,631	'
Research and development	5,297	4,474	14,684	14,528
General and administrative	8,117	5,440	23,571	18,635
Selling and marketing	3,801	6,026	11,461	15,967
Total costs and expenses	27,820	22,207	67,510	58,587
Income (loss) from operations	3,643	-1,044	10,183	6,517
Non-operating income (expense):	'	'	'	'
Interest income	26	20	106	63
Interest expense	-384	-461	-1,176	-1,449
Other income (expense), net	519	183	143	2,203
Total non-operating income (expense), net	161	-258	-927	817
Income (loss) before income taxes	3,804	-1,302	9,256	7,334
Income tax (provision) benefit	-2,324	2,825	-5,410	-2,641
Net income	1,480	1,523	3,846	4,693
Net income per share:	'	'	'	'
Basic (in Dollars per share)	$0.03	$0.04	$0.09	$0.11
Diluted (in Dollars per share)	$0.03	$0.04	$0.09	$0.11
Weighted average common shares outstanding:	'	'	'	'
Basic (in Shares)	43,796	41,863	43,613	41,644
Diluted (in Shares)	43,796	42,787	43,613	42,662
Net income	1,480	1,523	3,846	4,693
Other comprehensive income (loss):	'	'	'	'
Unrealized gain (loss) on investments, net of tax effect	-5	18	'	-16
Foreign currency translation	287	-253	42	-387
Comprehensive income	$1,762	$1,288	$3,888	$4,290

Condensed_Consolidated_Stateme1

Condensed Consolidated Statement of Changes in Stockholdersb Equity (Unaudited) (USD $)	Common Class A [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Total
	Common Stock [Member]
Balance at December 31, 2013 at Dec. 31, 2013	$432,000	$72,109,000	$15,601,000	($2,313,000)	($26,860,000)	$58,969,000
Balance at December 31, 2013 (in Shares) at Dec. 31, 2013	43,315,749	'	'	524,792	'	'
Employee stock option expense	'	1,379,000	'	'	'	1,379,000
Stock issued under exercise of stock options	5,000	2,162,000	'	'	'	2,167,000
Stock issued under exercise of stock options (in Shares)	472,640	'	'	'	'	'
Stock issued under employee stock purchase plan	'	23,000	'	'	'	23,000
Stock issued under employee stock purchase plan (in Shares)	3,555	'	'	'	'	'
Stock issued under "at-the-market" offering	6,000	5,321,000	'	'	'	5,327,000
Stock issued under "at-the-market" offering (in Shares)	538,521	'	'	'	'	'
Foreign currency translation	'	'	42,000	'	'	42,000
Windfall tax benefit from stock-based compensation	'	-97,000	'	'	'	-97,000
Net income	'	'	'	'	3,846,000	3,846,000
Balance at September 30, 2014 at Sep. 30, 2014	$443,000	$80,897,000	$15,643,000	($2,313,000)	($23,014,000)	$71,656,000
Balance at September 30, 2014 (in Shares) at Sep. 30, 2014	44,330,465	'	'	524,792	'	'

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:	'	'
Net income	$3,846	$4,693
Adjustments to reconcile net income to net cash provided by (used in) operating activities:	'	'
Depreciation and amortization	984	1,117
Intangible assets impairment	5,631	'
Deferred tax provision	48	-201
Deferred charge	2,576	504
Stock-based compensation	1,379	1,376
Amortization of premiums on investments	69	81
Unrealized currency translations	-301	-815
Accounts receivable	-3,047	-1,334
Unbilled accounts receivable	-2	732
Product royalties receivable	-1,982	581
Inventory	74	-218
Prepaid and income taxes receivable and payable, net	-4,091	-2,159
Accounts payable	-1,682	-2,428
Accrued expenses	1,501	-4,231
Deferred revenue	18	-3,039
Accrued interest payable	304	395
Other assets and liabilities, net	2,207	-2,247
Net cash provided by (used in) operating activities	7,532	-7,193
Cash flows from investing activities:	'	'
Purchases of investments	-12,224	-7,910
Proceeds from the sales of investments	1,700	'
Maturities of investments	11,750	5,760
Purchases of property and equipment	-62	-153
Changes in restricted cash	'	-9,561
Net cash provided by (used in) investing activities	1,164	-11,864
Cash flows from financing activities:	'	'
Proceeds from notes payable	'	10,600
Repayment of notes payable	-3,905	-3,725
Proceeds from exercise of stock options	2,167	1,543
Proceeds from employee stock purchase plan	23	17
Proceeds from "at-the-market" stock issuance	5,327	'
Purchase of treasury stock	'	-336
Windfall benefit from stock-based compensation	-97	304
Net cash provided by financing activities	3,515	8,403
Effect of exchange rates on cash and cash equivalents	-226	-1,457
Net increase (decrease) in cash and cash equivalents	11,985	-12,111
Cash and cash equivalents at beginning of period	44,102	52,022
Cash and cash equivalents at end of period	$56,087	$39,911

Note_1_Business_Organization_a

Note 1 - Business Organization and Basis of Presentation	9 Months Ended
	Sep. 30, 2014
Disclosure Text Block [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	'1.      Business Organization and Basis of Presentation
	Description of the Business
	Sucampo Pharmaceuticals, Inc. (the Company) is a global biopharmaceutical company focused on innovative research, discovery, development and commercialization of proprietary drugs to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders. Over the next five years, we intend to expand our management, organizational and operational capabilities, expand our global partnerships, develop our diversified product pipeline, acquire non-prostone clinical candidates, and enhance our capital structure.
	The Company currently generates revenue mainly from product royalties, development milestone payments, product sales and clinical development activities. The Company expects to continue to incur significant expenses for the next several years as the Company continues its research and development activities, seeks regulatory approvals and additional indications for approved products and other compounds, seeks global partnering opportunities for its approved products and compounds, and seeks strategic opportunities for non-prostone clinical candidates.
	In the United States (U.S.) 8 mcg and 24 mcg AMITIZA® (lubiprostone) capsules are marketed for three gastrointestinal indications under the October 2004 collaboration and license agreement (the Takeda Agreement) with Takeda Pharmaceutical Company Limited (Takeda). These three indications are: 1.) 24 mcg capsules for the treatment of chronic idiopathic constipation (CIC) in adults, 2.) 8 mcg capsules for the treatment of irritable bowel syndrome with constipation (IBS-C) in adult women, and 3.) 24 mcg capsules for the treatment of opioid-induced constipation (OIC) in adults suffering from chronic non-cancer pain. Under the Takeda Agreement the Company is primarily responsible for clinical development activities, while Takeda is primarily responsible for the commercialization of AMITIZA in the U.S. and Canada. Takeda also holds marketing rights to AMITIZA in Canada and the Company filed for regulatory approval in Canada at the end of October 2014. The Company and Takeda initiated commercial sales of AMITIZA in the U.S. for the treatment of CIC, IBS-C, and OIC in April 2006, May 2008 and May 2013, respectively. In September 2014, the Company and Takeda launched a pilot direct-to-consumer advertising campaign for AMITIZA in select U.S. markets for adults with CIC.
	In Japan, 24 mcg AMITIZA capsules are marketed under a license, commercialization and supply agreement (the Abbott Agreement) with Abbott Japan Co. Ltd. (Abbott Japan) for the gastrointestinal indication of chronic constipation (CC), excluding constipation caused by organic diseases. Abbott Japan initiated commercial sales of AMITIZA in Japan for the treatment of CC in November 2012. AMITIZA is Japan’s only prescription medicine for CC. The Company has been informed that Abbott Laboratories, Inc. has entered into an asset purchase agreement with Mylan, Inc. (Mylan), pursuant to which the Abbott Agreement will be sold to Mylan. The Company expects the transfer of the Abbott Agreement to Mylan will be completed in the first half of 2015, and the Company does not expect any significant changes in the commercialization of AMITIZA in Japan as a result of such transfer.
	Under the terms of the Abbott Agreement, Abbott Japan agreed to pay the Company a commercial milestone payment of $2.5 million within forty-five (45) days after the end of the month during which the first occurrence of annual net sales of lubiprostone in Japan exceeded ¥5.0 billion. On October 6, 2014, after confirming the October 2014 notification by Abbott Japan that annual net sales had exceeded ¥5.0 billion by the end of September 2014, the Company invoiced Abbott Japan $2.5 million for the commercial milestone payment. This revenue was recorded in the third quarter of 2014.
	The Company holds license agreements for RESCULA® (unoprostone isopropyl ophthalmic solution) 0.15% in the U.S. and Canada and the rest of the world, with the exception of Japan, Korea, Taiwan and the People’s Republic of China. RESCULA is approved in the U.S. for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The Company has ceased marketing RESCULA, and in the third quarter of 2014 incurred a $5.6 million intangible assets impairment related to RESCULA (see Note 5.)
	The Company’s other clinical development programs include the following:
	Pediatric Functional Constipation
	As previously disclosed, two of the four planned phase 3 studies for the Company’s pediatric functional constipation development program are ongoing, both of which are testing the 24 mcg soft gelatin capsule formulation of lubiprostone in patients 6 to 17 years of age: a 12-week, randomized, placebo-controlled trial that initiated in December 2013 and a follow-on, long-term safety extension study that initiated in March 2014.
	Alternate Formulation Lubiprostone
	As previously disclosed, the Company has been developing a new dosage form of lubiprostone for patients who will not swallow the soft gelatin capsule. Takeda has agreed to fund 100% of the costs for the alternate formulation work for lubiprostone. Feasibility testing for this alternate formulation work is ongoing and is expected to be completed in the first quarter of 2015.  If successful, the alternate formulation will enable future studies of lubiprostone in adults and younger children who will not swallow the current soft gelatin capsule formulation.
	Intravenous and Oral Ion Channel Activators for Lumbar Spinal Stenosis
	Two ion channel activators, in both the intravenous, or IV, and oral, or PO, forms, are in clinical development for the treatment of lumbar spinal stenosis (LSS). Positive top-line results from a phase 1b trial evaluating the safety and pharmacokinetics of the orally administered ion channel activator demonstrated the compound to be generally well-tolerated. The Company plans to initiate a phase 2a study with the orally administered compound in the second half of 2015 to evaluate the clinical effectiveness of the PO ion channel activator in patients with LSS. The Company has decided not to proceed with the IV version at this time.
	Cobiprostone as an Oral Spray for Oral Mucositis
	The Company has completed a phase 1b clinical trial for the target indication of prevention and/or treatment of oral mucositis. The results of this phase 1b trial showed that cobiprostone was well-tolerated and revealed low systemic exposure. The next phase of clinical development, a phase 2 trial, is expected to begin in the first half of 2015.
	Cobiprostone for Non-Erosive Reflux Disease (NERD)
	The Company announced it will begin a development program for cobiprostone to treat non-erosive reflux disease (NERD) for patients who have a non-satisfactory response to proton pump inhibitors.  The Company plans to initiate a phase 2 program in NERD by the end of 2014.
	Unoprostone isopropyl for Retinitis Pigmentosa (RP)
	The Company has received orphan drug designation for unoprostone isopropyl from the FDA for the treatment of retinitis pigmentosa (RP) and from European Medicines Agency.  In the first quarter of 2015 the Company will obtain interim, one-year data from the two-year Phase 3 study for RP in Japan, which is being funded by the Company's partner R-Tech Ueno.  The Company continues to work with clinical experts and regulators in the U.S. and Europe to determine a go-forward plan for development of RP in these markets.  Taken together, these will provide the Company with the information needed to decide on next steps in RP by mid-2015, with the aim to expand to a global program.  Additionally, the Company is evaluating opportunities in other retinal diseases, such as geographic atrophy, the advanced stage of age-related macular degeneration.
	Basis of Presentation
	The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and the rules and regulations of the U.S. Securities and Exchange Commission, or SEC, for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company’s Consolidated Financial Statements as of and for the year ended December 31, 2013 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on March 12, 2014. The financial information as of September 30, 2014 and for the three and nine months ended September 30, 2014 and September 30, 2013 is unaudited. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. In the opinion of the Company’s management, all adjustments, consisting only of normal recurring adjustments or accruals, considered necessary for a fair statement of the results of these interim periods have been included. The results of the Company’s operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year.
	The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries: Sucampo AG (SAG) based in Zug, Switzerland, through which the Company conducts certain of its worldwide and European operations; Sucampo Pharma, Ltd. (SPL) based in Tokyo and Osaka, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, (SPA) based in Bethesda, Maryland, through which the Company conducts its North and South American operations; and Sucampo Pharma Europe, Ltd., (SPE) based in Oxford, United Kingdom. The Company liquidated Ambrent Investments S.à.r.l., based in Luxembourg, at the end of 2013. All significant inter-company balances and transactions have been eliminated.
	The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
	Recent Accounting Pronouncements
	In April 2014, the Financial Accounting Standards Board (the FASB) issued Accounting Standards Update 2014-08, “Presentation of Financial Statements and Property, Plant and Equipment”. Under the new standard, only disposals representing a strategic shift in operations that have a major effect on the organization's operations and financial results, or a business activity classified as held for sale, should be presented as discontinued operations. Additionally, it expands the disclosure requirements for discontinued operations to provide more information regarding the assets, liabilities, income and expenses of discontinued operations. This update is effective for interim and annual periods beginning after December 15, 2014, and early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company's consolidated financial statements.
	In May 2014, the FASB issued Accounting Standards Update 2014-09, "Revenue from Contracts with Customers." While the standard supersedes existing revenue recognition guidance, it closely aligns with current GAAP. Under the new standard, revenue is recognized at the time a good or service is transferred to a customer for the amount of consideration received for that specific good or service. It is effective for annual reporting periods beginning after December 15, 2016, including interim reporting periods, and early adoption is not permitted. Entities may use a full retrospective approach or report the cumulative effect as of the date of adoption. The Company is currently evaluating the impact the adoption of this standard will have on the Company’s consolidated financial statements.
	In August 2014, the FASB issued Accounting Standards Update 2014-15, “Presentation of Financial Statements-Going Concern”. The new standard provides guidance regarding management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures. The new standard is effective for annual reporting periods beginning after December 15, 2016, including interim reporting periods, and early adoption is permitted. The Company is currently evaluating the impact of adopting this standard, but does not expect it will have a material impact on the Company’s consolidated financial statements.
	Revision to Previously Issued Financial Statements
	While preparing historical financial statements for the year ended December 31, 2013 and periods ended March 31, 2014 and June 2014, the Company identified certain immaterial errors in the presentation of certain line items in the previously reported financial statements. In accordance with ASC Topic 250, Accounting Changes and Error Corrections, ASC Topic 250-10-S99-1, Assessing Materiality, and ASC Topic 250-10-S99-2, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements, the Company evaluated these errors and, based on an analysis of quantitative and qualitative factors, determined that they were not material, individually or in aggregate to any previously issued financial statements and, therefore, amendment of previously filed reports with the SEC was not required.
	The Company has revised certain comparative periods to correct for these errors; however, certain account balances have not yet been revised. As a result, the Company is including herein the correction of all such immaterial errors that have not been revised in its previous periodic filings. The Company has revised the Condensed Consolidated Statements of Operations and Comprehensive Income for the three and nine months ended September 30, 2013 to correct errors in the presentation of gross profit.  As a result of this revision, gross profit was removed as a sub-total and costs of goods sold was disclosed as an operating cost under the heading “Costs and expenses”. Gross profit was presented on the Condensed Consolidated Statements of Operations and Comprehensive Income beginning in the year ended December 31, 2012 and for periods ended March 31, June 30 and September 30, 2013.
	In addition, the Company has revised the Consolidated Statements of Operations and Comprehensive Income for the year ended December 31, 2013 and 2012, the three months ended March 31, 2013 and March 31, 2014, the three and nine months ended September 30, 2013 and the Consolidated Balance Sheet as of December 31, 2013 and 2012 to correct errors in the recognition of indirect taxes at its Swiss subsidiary. The errors affect the years ended December 31, 2012 and 2013 and the periods ended March 31, 2013, June 30, 2013, September 30, 2013 and March 31, 2014. During those periods, the Company overstated its indirect tax liability and understated net income.
	The Company has also revised the Consolidated Statements of Cash Flows for the year ended December 31, 2013 and the nine months ended September 30, 2013 to correct errors in the classification of foreign exchange gains and losses in net cash used in operating activities, investing activities and the effect of exchange rates on cash and cash equivalents and the change in net income. The errors in classification affect the year ended December 31, 2013 and the periods ended September 30, 2013, June 30, 2013 and March 31, 2013. These errors have no effect on the balances of cash and cash equivalents.
	Selected Items - Annual	As			Revision			As Revised
		Previously			Adjustment
		Reported
	Consolidated Balance Sheet
	(In thousands)	Presentation as of December 31, 2012
	Other liabilities	$	1,253		$	(225	)	$	1,028
	Total liabilities		84,766			(225	)		84,541
	Accumulated deficit		(34,100	)		225			(33,875	)
	Total stockholders' equity		43,030			225			43,255
	Consolidated Statements of Operations
	and Comprehensive Income
	(In thousands)	Presentation as of the year ended December 31, 2012
	Other income (expense), net	$	1,602		$	225		$	1,827
	Total non-operating income (expense), net		(565	)		225			(340	)
	Income (loss) before income taxes		7,752			225			7,977
	Net income		4,836			225			5,061
	Comprehensive income		3,148			225			3,373
	Consolidated Statements of Operations
	and Comprehensive Income
	(In thousands, except per share data)	Presentation as of the year ended December 31, 2013
	Other income (expense), net	$	2,921		$	596		$	3,517
	Total non-operating income (expense), net		1,151			596			1,747
	Income (loss) before income taxes		10,347			596			10,943
	Net income		6,419			596			7,015
	Net income per share: Basic		0.15			0.02			0.17
	Net income per share: Diluted		0.15			0.01			0.16
	Comprehensive income		5,854			596			6,450
	Consolidated Statements of Cash Flows
	(In thousands)	Presentation as of the year ended December 31, 2013
	Net cash provided by (used in) operating activities	$	(5,418	)	$	1,209		$	(4,209	)
Net cash provided by (used in) investing activities		(13,881	)		1,265			(12,616	)
Effect of exchange rates on cash and cash equivalents		798			(2,474	)		(1,676	)
Selected Items - Quarterly	As			Revision			As Revised
	Previously			Adjustment
	Reported
Consolidated Balance Sheet
(In thousands)	Presentation as of March 31, 2014
Other Assets	$	455		$	28		$	483
Other liabilities		1,596			(917	)		679
Total liabilities		78,839			(917	)		77,922
Accumulated deficit		(27,006	)		945			(26,061	)
Total stockholders' equity		65,406			945			66,351
Consolidated Statements of Operations
and Comprehensive Income
(In thousands)	Presentation as of the three months ended March 31, 2014
Other income (expense), net	$	(323	)	$	124		$	(199	)
Total non-operating income (expense), net		(666	)		124			(542	)
Income (loss) before income taxes		1,939			124			2,063
Income tax benefit (provision)		(1,264	)		(44	)		(1,308	)
Net income		675			80			755
Comprehensive income		564			80			644
Consolidated Balance Sheet
(In thousands)	Presentation as of March 31, 2013
Other liabilities	$	1,210		$	(293	)	$	917
Total liabilities		93,348			(293	)		93,055
Accumulated deficit		(37,245	)		293			(36,952	)
Total stockholders' equity		40,003			293			40,296
Consolidated Statements of Operations
and Comprehensive Income
(In thousands, except per share data)	Presentation as of the three months ended March 31, 2013
Other income (expense), net	$	1,081		$	69		$	1,150
Total non-operating income (expense), net		605			69			674
Income (loss) before income taxes		(2,003	)		69			(1,934	)
Net income		(3,145	)		69			(3,076	)
Net income per share: Basic		(0.08	)		0.01			(0.07	)
Net income per share: Diluted		(0.08	)		0.01			(0.07	)
Comprehensive income		(3,108	)		69			(3,039	)
Selected Items - Quarterly	As			Revision			As Revised
	Previously			Adjustment
	Reported
Consolidated Balance Sheet
(In thousands)	Presentation as of September 30, 2013
Other liabilities	$	1,296		$	(651	)	$	645
Total liabilities		79,923			(651	)		79,272
Accumulated deficit		(29,834	)		651			(29,183	)
Total stockholders' equity		49,797			651			50,448
	As Previously Reported						Revision Adjustment						As Revised
Condensed Consolidated Statements of Operations	Three			Nine			Three			Nine			Three			Nine
and Comprehensive Income	Months			Months			Months			Months			Months			Months
	Ended			Ended			Ended			Ended			Ended			Ended
(In thousands, except per share data)	30-Sep-13
Gross profit	$	14,896		$	55,647		$	(14,896	)	$	(55,647	)	$	0		$	0
Total costs and expenses		(15,940	)		(49,130	)		(6,267	)		(9,457	)		(22,207	)		(58,587	)
Other income (expense), net		(49	)		1,776			232			427			183			2,203
Total non-operating income (expense), net		(490	)		390			232			427			(258	)		817
Income (loss) before income taxes		(1,534	)		6,907			232			427			(1,302	)		7,334
Net income		1,291			4,266			232			427			1,523			4,693
Net income per share: Basic		0.03			0.1			0.01			0.01			0.04			0.11
Net income per share: Diluted		0.03			0.1			0.01			0.01			0.04			0.11
Comprehensive income		1,056			3,863			232			427			1,288			4,290
Condensed Consolidated Statements of Cash Flows
(In thousands)	Presentation as of the nine months ended September 30, 2013
Net cash provided by (used in) operating activities	$	(8,178	)	$	985		$	(7,193	)
Net cash provided by (used in) investing activities		(12,334	)		470			(11,864	)
Effect of exchange rates on cash and cash equivalents		(2	)		(1,455	)		(1,457	)
Condensed Consolidated Statements of Operations
and Comprehensive Income
(In thousands, except per share data)	Presentation as of the three months ended December 31, 2013
Net Income (loss)	$	2,153		$	170		$	2,323
Net income per share: Basic		0.05			0.01			0.06
Condensed Consolidated Statements of Operations
and Comprehensive Income
(In thousands, except per share data)	Presentation as of the three months ended December 31, 2012
Net Income (loss)	$	13,532		$	225		$	13,757
Net income per share: Diluted		0.32			0.01			0.33

Note_2_Summary_of_Significant_

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	2.      Summary of Significant Accounting Policies
	Restricted Cash
	Restricted cash primarily represents collateral pledged to support a loan agreement with The Bank of Tokyo-Mitsubishi UFJ, Ltd., or the Tokyo-Mitsubishi Bank; a loan agreement with The Mizuho Bank, Ltd., or the Mizuho Bank; a loan agreement between Numab AG, or Numab, and Zurcher Kantonalbank, or the Numab Loan, under which the Company serves as guarantor; and operating leases with certain financial institutions. Restricted cash totaled approximately $28.4 million at September 30, 2014 and $28.6 million at December 31, 2013.
	Certain Risks, Concentrations and Uncertainties
	Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents, restricted cash, investments and receivables. The Company places its cash, cash equivalents and restricted cash with highly rated financial institutions and invests its excess cash in highly rated investments. As of September 30, 2014 and December 31, 2013, approximately $21.2 million, or 19.9%, and $16.4 million, or 17.1%, respectively, of the Company’s cash, cash equivalents, restricted cash and investments were issued or insured by the United States government or United States government agencies. The Company has not experienced any losses on these accounts related to amounts in excess of insured limits.
	Revenues from Takeda, an unrelated party, accounted for 62.4% and 73.9% of the Company’s total revenues for the three months ended September 30, 2014 and 2013, respectively, and 66.7% and 82.9% for the nine months ended September 30, 2014 and 2013, respectively. Accounts receivable, unbilled accounts receivable and product royalties receivable from Takeda accounted for 72.4% and 88.2% of the Company’s total accounts receivable, unbilled accounts receivable and product royalties receivable at September 30, 2014 and December 31, 2013, respectively.
	Revenues from another unrelated party, Abbott, accounted for 36.2% and 24.5% of the Company’s total revenues for the three months ended September 30, 2014 and 2013, respectively, and 31.8% and 16.4% for the nine months ended September 30, 2014 and 2013, respectively.
	The Company depends significantly upon its collaborations with Takeda and Abbott, and its revenues may be adversely impacted if these relationships are disrupted.
	Fair Value of Financial Instruments
	The carrying amounts of the Company’s financial instruments approximate their fair values based on their short maturities, independent valuations or internal assessments. The Company’s financial instruments include cash and cash equivalents, restricted cash, current and non-current investments, receivables, accounts payable and accrued expenses. The carrying amounts of the notes payable at September 30, 2014 and December 31, 2013 were less than the estimated fair values (see Note 9 below).
	Accounts Receivable and Unbilled Accounts Receivable
	The Company’s allowance for doubtful accounts related to certain disputed Takeda invoices totaled approximately $796,000 and $440,000 as of September 30, 2014 and December 31, 2013, respectively.

Note_3_Net_Income_Per_Share

Note 3 - Net Income Per Share	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	3.      Net Income per Share
	Basic net income per share is computed by dividing net income by the sum of the weighted average class A common shares outstanding. Diluted net income per share is computed by dividing net income by the weighted average common shares and potential dilutive common shares outstanding. Diluted net loss per share, when applicable, is computed by dividing net loss by the weighted average common shares outstanding without the impact of potential dilutive common shares outstanding because they would have an anti-dilutive impact on diluted net loss per share.
	The computation of net income per share for the three and nine months ended September 30, 2014 and 2013 is shown below:
		Three Months Ended September 30,				Nine Months Ended September 30,
	(In thousands, except per share data)	2014		2013		2014		2013
	Basic net income per share:
	Net income	$	1,480	$	1,523	$	3,846	$	4,693
	Weighted average class A common shares outstanding		43,796		41,863		43,613		41,644
	Basic net income per share	$	0.03	$	0.04	$	0.09	$	0.11
	Diluted net income per share:
	Net income	$	1,480	$	1,523	$	3,846	$	4,693
	Weighted average class A common shares outstanding		43,796		41,863		43,613		41,644
	Assumed exercise of stock options under the treasury stock method		-		924		-		1,018
			43,796		42,787		43,613		42,662
	Diluted net income per share	$	0.03	$	0.04	$	0.09	$	0.11
	The following securities were excluded from the computation of diluted net income per share for the three and nine months ended September 30, 2014 and 2013 as their effect would be anti-dilutive:
		Three Months Ended September 30,				Nine Months Ended September 30,
	(In thousands)	2014		2013		2014		2013
	Employee stock options		1,759		576		438		576

Note_4_Current_and_NonCurrent_

Note 4 - Current and Non-Current Investments	9 Months Ended
	Sep. 30, 2014
Investments Schedule [Abstract]	'
Investment [Text Block]	'
	4.      Current and Non-Current Investments
	At September 30, 2014 and December 31, 2013, current and non-current available-for-sale investments consisted of the following securities:
		30-Sep-14
	(In thousands)	Cost		Unrealized		Unrealized			Fair Value
				Gains		Losses
	Current:
	Commercial paper	$	400	$	-	$	-		$	400
	U.S. government agencies		4,205		2		-			4,207
	Certificates of deposits		4,250		-		-			4,250
	Total	$	8,855	$	2	$	-		$	8,857
	Non-current:
	U.S. government agencies	$	8,055	$	-	$	(24	)	$	8,031
	Certificates of deposit		4,000		-		-			4,000
	Corporate bonds		1,018		-		(3	)		1,015
	Total	$	13,073	$	-	$	(27	)	$	13,046
		31-Dec-13
	(In thousands)	Cost		Unrealized		Unrealized			Fair Value
				Gains		Losses
	Current:
	U.S. government securities	$	1,000	$	-	$	-		$	1,000
	U.S. government agencies		9,048		3		-			9,051
	Certificates of deposit		3,500		-		-			3,500
	Corporate bonds		752		-		-			752
	Municipal securities		1,700		-		-			1,700
	Total	$	16,000	$	3	$	-		$	16,003
	Non-current:
	U.S. government agencies	$	4,212	$	-	$	(3	)	$	4,209
	Certificates of deposits		2,500		-		-			2,500
	Corporate bonds		511		-		(1	)		510
	Total	$	7,223	$	-	$	(4	)	$	7,219
	The Company performs fair value measurements in accordance with the Financial Accounting Standards Board’s guidance for fair value measurements and disclosures, which defines fair value as the exchange price that would be received for selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy is established which requires the Company to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company classifies its investments into the following categories based on the three levels of inputs used to measure fair value:
	Level 1: quoted prices in active markets for identical assets or liabilities;
	Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or
	Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The Company’s assets measured at fair value on a recurring basis, including cash equivalents, which are subject to the fair value disclosure requirements, at September 30, 2014 and December 31, 2013, were as follows:
		Fair Value Measurements at Reporting Date Using
	(In thousands)	Quoted Prices		Significant		Significant			Total
		in Active		Other		Unobservable
		Markets for		Observable		Inputs
		Identical		Inputs		(Level 3)
		Assets		(Level 2)
		(Level 1)
	Commercial paper	$	-	$	8,499	$	-		$	8,499
	U.S. government agencies		-		12,239		-			12,239
	Certificates of deposit		-		8,250		-			8,250
	Corporate bonds		-		3,622		-			3,622
	Money market funds		7,573		-		-			7,573
	Total assets measured at fair value	$	7,573	$	32,610	$	-		$	40,183
		Fair Value Measurements at Reporting Date Using
	(In thousands)	Quoted Prices		Significant		Significant			Total
		in Active		Other		Unobservable
		Markets for		Observable		Inputs
		Identical Assets		Inputs		(Level 3)
		(Level 1)		(Level 2)
	U.S. government securities	$	-	$	1,000	$	-		$	1,000
	U.S. government agencies		-		13,260		-			13,260
	U.S. commercial paper		-		6,449		-			6,449
	Municipal securities		-		1,700		-			1,700
	Certificates of deposit		-		6,000		-			6,000
	Corporate bonds		-		5,533		-			5,533
	Money market funds		5,955		-		-			5,955
	Total assets measured at fair value	$	5,955	$	33,942	$	-		$	39,897
	If quoted prices in active markets for identical assets and liabilities are not available to determine fair value, then the Company uses quoted prices for similar assets and liabilities or inputs other than the quoted prices that are observable, either directly or indirectly. This pricing methodology applies to the Company’s Level 2 investments.

Note_5_Intangible_Assets

Note 5 - Intangible Assets	9 Months Ended
	Sep. 30, 2014
Disclosure Text Block [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	5.      Intangible Assets
	The Company reviews definite lived intangible assets for impairment when events or changes in circumstances indicate that the carrying value of its intangible assets may not be recoverable. The carrying value of an intangible asset is assessed for impairment whenever anticipated future undiscounted cash flows from an intangible asset are estimated to be less than its carrying value. The amount of impairment loss recognized is the amount the carrying value exceeds its fair value.
	During the three months ended September 30, 2014 the Company made the decision to cease RESCULA direct commercialization activities and will no longer market RESCULA for its approved U.S. Food and Drug Administration (FDA) indication. During the three months ended September 30, 2014 the company recorded an impairment charge of $5.6 million which represented the full amount of the remaining balances of the unamortized intangibles related to its two RESCULA license agreements described below. Fair value was determined based on an income approach. Both license agreements were for the development and commercialization of RESCULA for its approved indication and for any new indications for unoprostone isopropyl. Of the total impairment charge, $1.5 million is included in the Company’s Americas segment, and $4.1 million is included in the Company’s Europe segment. There were no impairment charges recorded during the three months ended September 30, 2013.
	In April 2009, the Company entered into an agreement with R-Tech (the 2009 R-Tech Agreement) to license all patents and other intellectual property rights related to RESCULA for its FDA approved indication and any new indications for unoprostone isopropyl in the United States and Canada. A supplemental new drug application for RESCULA (unoprostone isopropyl ophthalmic solution) 0.15% for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension was approved by the FDA in December 2012 and the Company began commercializing the product in February 2013.
	Under the terms of the 2009 R-Tech Agreement, the Company made upfront and milestone payments totaling $3.5 million, of which $3.4 million was allocated to an intangible asset. The $3.4 million is included in intangible assets, net in the accompanying Condensed Consolidated Balance Sheet as of December 31, 2013. During the three months ended September 30, 2014 the Company ceased direct commercialization activities of RESCULA and has fully impaired the unamortized value of this intangible asset resulting in a charge of $1.5 million. The Company had been amortizing the $3.4 million intangible over the 10-year life of the 2009 R-Tech Agreement, which the Company believed approximated the useful life of the underlying rights and data for the approved FDA indication. Amortization expense was approximately $57,000 and $85,000 for the three months ended September 30, 2014 and 2013, respectively, and approximately $227,000 and $256,000 for the nine months ended September 30, 2014 and 2013, respectively. The unamortized amount included in intangible assets was nil at September 30, 2014 and $1.8 million at December 31, 2013, respectively.
	In March 2011, the Company entered into a license agreement with R-Tech for unoprostone isopropyl, or the 2011 R-Tech Agreement, expanding the Company’s development and commercialization rights as well as its territories beyond their previously agreed territory of the United States and Canada to the rest of the world, with the exception of Japan, Korea, Taiwan and the People’s Republic of China. Pursuant to the 2011 R-Tech Agreement, the Company made payments to R-Tech of $6.0 million, which is reflected in intangible assets, net in the accompanying Condensed Consolidated Balance Sheet as of December 31, 2013. The Company has fully impaired the unamortized value of this intangible asset during the three months ended September 30, 2014 resulting in a charge of $4.1 million. The Company had been amortizing the $6.0 million intangible over the 10-year life of the 2011 R-Tech Agreement which the Company believed approximated the useful life of the underlying rights and data for the indication previously approved in Europe. Amortization expense was approximately $102,000 and $153,000 for the three months ended September 30, 2014 and 2013, respectively, and approximately $409,000 and $460,000 for the nine months ended September 30, 2014 and 2013, respectively. The unamortized amount included in intangible assets was nil at September 30, 2014 and $4.4 million at December 31, 2013, respectively.

Note_6_Accrued_Expenses

Note 6 - Accrued Expenses	9 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	6.      Accrued Expenses
	Accrued expenses consist of the following as of September 30, 2014 and December 31, 2013:
	(In thousands)	September 30,		December 31,
		2014		2013
	Research and development costs	$	2,826	$	1,775
	Employee compensation		2,488		2,531
	Selling and marketing costs		305		584
	Legal service fees		983		14
	Other accrued expenses		558		778
	Total	$	7,160	$	5,682

Note_7_Commitments

Note 7 - Commitments	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	7.       Commitments
	Operating Leases
	The Company leases office space in the United States, Switzerland and Japan under operating leases through 2018. Total future minimum, non-cancelable lease payments under the Company's operating leases are as follows as of September 30, 2014:
	(In thousands of U.S. dollars)	September 30,
		2014
	2014	$	354
	2015		1,258
	2016		1,290
	2017		345
	2018		204
	Total minimum lease payments	$	3,451
	Rent expense for all operating leases was approximately $343,000 and $323,000 for the three months ended September 30, 2014 and 2013, respectively, and $1.0 million for both the nine months ended September 30, 2014 and 2013, respectively.
	Research and Development Costs
	The Company routinely enters into agreements with third-party contract research organizations to oversee clinical research and development studies provided on an outsourced basis, and to assist in other research and development activities. The Company generally is not contractually obligated to pay the third party if the service or reports are not provided. Total future estimated costs under these agreements as of September 30, 2014 were approximately $6.9 million.
	Numab Commitment
	In the event that Numab defaults under the Numab Loan, the Company’s maximum contingent liability under the Numab Agreement (see Note 8) is $2.3 million. As of September 30, 2014, the potential amount of payments in the event of Numab’s default under the Numab Loan was $2.1 million.  At September 30, 2014 and December 31, 2013, the Company had a recorded liability of $1.0 million and $663,000, respectively, to meet a potential loan default by Numab.

Note_8_Related_Party_Transacti

Note 8 - Related Party Transactions	9 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	8.      Related Party Transactions
	R-Tech Ueno, Ltd.
	The Company recorded the following expenses for the three and nine months ended September 30, 2014 and 2013 under all of its agreements with R-Tech, including the 2009 R-Tech Agreement, the 2011 R-Tech Agreement and various exclusive supply agreements with R-Tech:
		Three Months Ended September 30,				Nine Months Ended September 30,
	(In thousands)	2014		2013		2014		2013
	Clinical supplies	$	88	$	35	$	254	$	255
	Other research and development services		139		75		170		181
	Commercial supplies		4,507		3,173		12,133		7,906
		$	4,734	$	3,283	$	12,557	$	8,342
	The following table summarizes the amounts included in deferred revenue resulting from the deferral of upfront payments relating to the exclusive supply agreements with R-Tech as of September 30, 2014 and December 31, 2013:
	(In thousands)	September 30,		December 31,
		2014		2013
	Deferred revenue, current	$	369	$	477
	Deferred revenue, non-current		4,473		4,925
		$	4,842	$	5,402
	The Company recognized approximately $160,000 and $105,000 of revenue relating to its agreements with R-Tech for the three months ended September 30, 2014 and 2013, respectively, and approximately $369,000 and $373,000 for the nine months ended September 30, 2014 and 2013, respectively. Such revenue was recorded as contract and collaboration revenue in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Income.
	Numab AG
	In September 2011, the Company entered into a Loan Guarantee and Development Agreement, or the Numab Agreement, with Numab. Numab is a related party of the Company as a result of the Company hiring as an executive officer an individual who holds an ownership interest in Numab. Under the terms of the Numab Agreement, the Company provided Numab with CHF 5.0 million as collateral and serves as guarantor for Numab on a loan from a third party, Zurcher Kantonalbank. During the first quarter of 2013, the collateral amount was reduced to CHF 2.2 million, or approximately $2.3 million as of September 30, 2014. As of September 30, 2014, Numab has utilized CHF 2.0 million of its loan facility, or approximately $2.1 million.

Note_9_Notes_Payable

Note 9 - Notes Payable	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	9.      Notes Payable
	In November 2010, the Company entered into a secured term loan agreement with the Tokyo-Mitsubishi Bank for ¥1.0 billion, approximating $11.6 million as of the closing date. The loan renews every November. The interest rate at September 30, 2014 was 1.21%. The outstanding loan balances included in the accompanying Condensed Consolidated Balance Sheets were $9.1 million and $9.5 million as of September 30, 2014 and December 31, 2013, respectively. A deposit of $14.9 million with the Tokyo-Mitsubishi Bank collateralizing the loan bears annual interest of 0.25%.
	In March 2013, the Company entered into a secured term loan agreement with the Mizuho Bank for ¥1.0 billion, approximating $10.6 million as of the closing date. The interest rate at September 30, 2014 was 0.46%. The loan renews every March. The outstanding loan balances included in the accompanying Condensed Consolidated Balance Sheets were $9.1 million and $9.5 million as of September 30, 2014 and December 31, 2013, respectively. A deposit of $11.0 million with the Mizuho Bank collateralizing the loan bears annual interest of 0.30%.
	In connection with the Company’s acquisition of SAG in 2010, the Company issued a subordinated unsecured promissory note to each of the Ueno and Kuno Trusts. The interest rate beginning June 1, 2014 is 4.32%.
	Due to changes in LIBOR rates, the Company has estimated the fair value of the notes payable as shown in the table below.
	Notes payable at their fair value and carrying value consist of the following as of September 30, 2014 and December 31, 2013:
		Fair Value				Carrying Value
	(In thousands)	September 30,		December 31,		September 30,		December 31,
		2014		2013		2014		2013
	Loan agreements	$	18,276	$	19,008	$	18,276	$	19,008
	Promissory notes, Sellers of SAG		30,984		34,889		29,807		33,712
		$	49,260	$	53,897	$	48,083	$	52,720
	Notes payable, current					$	26,342	$	26,892
	Notes payable, non-current						21,741		25,828
						$	48,083	$	52,720
	The Company’s debt is subject to the fair value disclosure requirements as discussed in Note 4 above, and is classified as a Level 2 security.

Note_10_Collaboration_and_Lice

Note 10 - Collaboration and License Agreements	9 Months Ended
	Sep. 30, 2014
Collaborative And License Arrangement Disclosure [Abstract]	'
Collaborative And License Arrangement Disclosure [Text Block]	'
	10.      Collaboration and License Agreements
	Abbott Agreement
	Under the Abbott Agreement, the Company has received a total of $37.5 million in upfront, development and commercial milestone payments through September 30, 2014. Additionally, on October 6, 2014, the Company invoiced Abbott $2.5 million pursuant to the Abbott Agreement for a commercial milestone payment as a result of the first occurrence of annual net sales of lubiprostone in Japan exceeding ¥5.0 billion. This milestone payment was recognized in the third quarter of 2014 and is expected to be received in the fourth quarter of 2014.
	The following table summarizes the cash streams and related revenue recognized or deferred under the Abbott Agreements for the nine months ended September 30, 2014:
	(In thousands)	Amount		Cash Received		Revenue		Change in Accounts		Foreign			Amount
		Deferred at		for the Nine		Recognized for		Receivable for the		Currency Effects			Deferred at
		December 31,		Months Ended		the Nine		Nine Months Ended		for the Nine			September 30,
		2013		September 30,		Months Ended		September 30,		Months Ended			2014
				2014		September 30,		2014		September 30,
						2014				2014
	Collaboration revenue:
	Up-front payment associated with the Company's obligation to participate in joint committees	$	555	$	-	$	30	$	-	$	(20	)	$	505
	Product sales revenue	$	-	$	20,775	$	22,206	$	1,824	$	(393	)	$	-
	Product sales milestone	$	-	$	-	$	2,500	$	2,500	$	-		$	-
	Takeda Agreements
	Under the Takeda Agreements, the Company has received a total of $160.0 million in upfront, development and commercial milestone payments through September 30, 2014.
	The following table summarizes the cash streams and related revenue recognized or deferred under the Takeda Agreements for the nine months ended September 30, 2014:
	(In thousands)	Amount		Cash Received		Revenue		Change in Accounts		Amount
		Deferred at		for the Nine		Recognized for		Receivable for the		Deferred at
		December 31,		Months Ended		the Nine		Nine Months Ended		September 30,
		2013		September 30,		Months Ended		September 30,		2014
				2014		September 30,		2014*
						2014
	Collaboration revenue:
	Up-front payment associated with participate in joint committees	$	1,029	$	-	$	73	$	-	$	956
	Research and development revenue:
	Reimbursement of research and development expenses	$	419	$	7,200	$	5,281	$	112	$	2,450
	Product royalty revenue	$	-	$	42,218	$	44,200	$	1,982	$	-
	Co-promotion revenue	$	-	$	1,381	$	2,021	$	640	$	-
	*      Includes billed and unbilled accounts receivable.

Note_11_Stock_Option_Plans

Note 11 - Stock Option Plans	9 Months Ended
	Sep. 30, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	11.      Stock Option Plans
	A summary of employee stock option activity for the nine months ended September 30, 2014 under the Company’s Amended and Restated 2001 Stock Incentive Plan, or the 2001 Stock Incentive Plan, is presented below:
		Shares			Weighted		Weighted		Aggregate
					Average		Average		Intrinsic Value
					Exercise Price		Remaining
					Per Share		Contractual
							Term (Years)
	Options outstanding, December 31, 2013		146,200		$	10
	Options expired		(25,500	)		10
	Options outstanding, September 30, 2014		120,700			10		1.59	$	-
	Options exercisable, September 30, 2014		120,700			10		1.59	$	-
	A summary of employee stock option activity for the nine months ended September 30, 2014 under the Company’s Amended and Restated 2006 Stock Incentive Plan is presented below:
		Shares			Weighted		Weighted		Aggregate
					Average		Average		Intrinsic Value
					Exercise Price		Remaining
					Per Share		Contractual
							Term (Years)
	Options outstanding, December 31, 2013		2,513,063		$	5.03
	Options granted		1,861,745			7.29
	Options exercised		(405,140	)		4.36
	Options forfeited		(209,493	)		4.59
	Options expired		(193,275	)		4.81
	Options outstanding, September 30, 2014		3,566,900			6.33		8.42	$	3,085,216
	Options exercisable, September 30, 2014		958,582			5.93		6.35	$	1,402,961
	Performance-based stock options granted to the CEO totaled 200,000 and vest when the Company’s stock price meets or exceeds $16.00 over a continuous 30 day trading period. These options expire on the four year anniversary of the grant if not vested at that time, and if vested, expire on July 30, 2028. The Company used a Monte Carlo approach and a Geometric Brownian Motion stock-pricing model to estimate the fair value of these options. During the quarter ended September 30, 2014, the Company granted time-based stock options to all eligible employees. For certain eligible employees, the granted stock options had accelerated vesting conditions. Those accelerated-vesting conditions applied to 450,000 stock options and cliff vest after four years, but one third of the total award may vest each time certain pre-determined strategic objectives of the Company have been met. The granted stock options expire ten years from date of grant, and the Company used a Black-Scholes option-pricing model to estimate the fair value of these options. Time-based stock options granted totaled 341,745 and vest in equal annual installments over four years from date of grant and expire ten years from date of grant. The Company used a Black-Scholes option-pricing model to estimate the fair value of these options.
	The weighted average grant date fair value of options granted during the nine months ended September 30, 2014 and the year ended December 31, 2013 was $7.29 and $7.36, respectively. As of September 30, 2014, approximately $5.3 million of total unrecognized compensation costs, net of estimated forfeitures related to non-vested awards, are expected to be recognized over a weighted average period of 3.32 years.
	A summary of non-employee stock option activity for the nine months ended September 30, 2014 under the Company’s 2001 Stock Incentive Plan is presented below:
		Shares			Weighted		Weighted		Aggregate
					Average		Average		Intrinsic Value
					Exercise Price		Remaining
					Per Share		Contractual
							Term (Years)
	Options outstanding, December 31, 2013		410,000		$	5.85
	Options exercised		(67,500	)		5.85
	Options outstanding, September 30, 2014		342,500			5.85		0.58	$	222,625
	Options exercisable, September 30, 2014		342,500			5.85		0.58	$	222,625
	Employee Stock Purchase Plan
	Under the Company’s 2006 Employee Stock Purchase Plan, the Company received $9,670 and $6,416 upon employees’ purchase of 1,566 and 1,082 shares of class A common stock during the three months ended September 30, 2014 and 2013, respectively, and $22,896 and $17,411 upon employees’ purchase of 3,555 and 2,846 shares of class A common stock during the nine months ended September 30, 2014 and 2013, respectively.

Note_12_Income_Taxes

Note 12 - Income Taxes	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	12.      Income Taxes
	For the three months ended September 30, 2014 and 2013, the Company recorded a tax provision of $2.3 million and a tax benefit of $2.8 million, respectively. For the nine months ended September 30, 2014 and 2013, the Company recorded tax provisions of $5.4 million and $2.6 million, respectively.  The tax provision for the three and nine months ended September 30, 2014 primarily pertained to the pre-tax income and losses generated by the Company’s U.S., Japanese and Swiss subsidiaries. The tax benefit for the three months ended September 30, 2013 primarily pertained to the pre-tax losses generated by the Company’s U.S. subsidiary. The tax provision for the nine months ended September 30, 2013 primarily pertained to pre-tax income generated by the Company’s U.S. and Japanese subsidiaries.
	The Company evaluated the need for a valuation allowance in foreign jurisdictions and concluded based on the most recent forecast of future income that it is more likely than not that it will not realize the benefit of a portion of its deferred tax assets in Japan; therefore, a discrete tax expense of approximately $517,000 was recorded for the three months ended September 30, 2014 to increase the valuation allowance. The Company will continue to evaluate the need for a valuation allowance in all foreign jurisdictions. Any release of valuation allowance would have a positive impact on the effective tax rate for the period.
	Uncertain Tax Positions
	The Company had an outstanding non-current income tax liability of approximately $969,000, including interest, for uncertain tax positions as of September 30, 2014. The amount represented the aggregate tax effect of differences between tax return positions and the amounts otherwise recognized in the Company’s Condensed Consolidated Financial Statements. As of September 30, 2014, $969,000 is reflected as other liabilities in the accompanying Condensed Consolidated Balance Sheets. The liability for uncertain tax positions as of September 30, 2014 mainly pertained to the Company’s interpretation of nexus in certain states related to revenue sourcing for state income tax purposes. During the three and nine months ended September 30, 2014, the liability for income taxes has decreased approximately $2,000 and increased approximately $290,000, respectively. These changes in the liability are primarily related to the filing positions taken in various jurisdictions related to income tax nexus.

Note_13_Segment_Reporting

Note 13 - Segment Reporting	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	13.           Segment Reporting
	The following is a summary of financial information for the Company’s reportable geographic segments:
	(In thousands)	Americas			Europe			Asia			Consolidated
	Three Months Ended September 30, 2014
	Research and development revenue	$	1,797		$	-		$	-		$	1,797
	Product royalty revenue		16,811			-			-			16,811
	Product sales revenue		170			142			11,405			11,717
	Co-promotion revenue		936			-			-			936
	Contract and collaboration revenue		141			51			10			202
	Total revenues		19,855			193			11,415			31,463
	Costs of goods sold		79			318			4,577			4,974
	Intangible assets impairment		1,502			4,129			-			5,631
	Research and development expenses		2,733			1,893			671			5,297
	Depreciation and amortization		140			116			7			263
	Other operating expenses		8,626			2,630			399			11,655
	Income (loss) from operations		6,775			(8,893	)		5,761			3,643
	Interest income		24			2			-			26
	Interest expense		(343	)		-			(41	)		(384	)
	Other non-operating income (expense), net		29			(443	)		933			519
	Income (loss) before income taxes	$	6,485		$	(9,334	)	$	6,653		$	3,804
	Capital expenditures	$	13		$	-		$	-		$	13
	Three Months Ended September 30, 2013
	Research and development revenue	$	2,027		$	-		$	-		$	2,027
	Product royalty revenue		13,595			-			-			13,595
	Product sales revenue		170			17			5,191			5,378
	Co-promotion revenue		-			-			-			-
	Contract and collaboration revenue		141			12			10			163
	Total revenues		15,933			29			5,201			21,163
	Costs of goods sold		3,389			4			2,874			6,267
	Research and development expenses		3,860			(305	)		919			4,474
	Depreciation and amortization		309			47			8			364
	Other operating expenses		8,893			1,646			563			11,102
	Income (loss) from operations		(518	)		(1,363	)		837			(1,044	)
	Interest income		18			2			-			20
	Interest expense		-			(417	)		(44	)		(461	)
	Other non-operating income, net		6			95			82			183
	Income (loss) before income taxes	$	(494	)	$	(1,683	)	$	875		$	(1,302	)
	Capital expenditures	$	9		$	4		$	-		$	13
	(In thousands)	Americas			Europe			Asia			Consolidated
	Nine Months Ended September 30, 2014
	Research and development revenue	$	5,281		$	-		$	-		$	5,281
	Product royalty revenue		44,200			-			-			44,200
	Product sales revenue		551			297			24,724			25,572
	Co-promotion revenue		2,021			-			-			2,021
	Contract and collaboration revenue		424			165			30			619
	Total revenues		52,477			462			24,754			77,693
	Cost of goods sold		375			357			11,431			12,163
	Intangible assets impairment		1,502			4,129			-			5,631
	Research and development expenses		7,565			4,528			2,591			14,684
	Depreciation and amortization		514			448			22			984
	Other operating expenses		25,306			7,364			1,378			34,048
	Income (loss) from operations		17,215			(16,364	)		9,332			10,183
	Interest income		67			6			33			106
	Interest expense		(1,054	)		-			(122	)		(1,176	)
	Other non-operating income (expense), net		31			547			(435	)		143
	Income (loss) before income taxes	$	16,259		$	(15,811	)	$	8,808		$	9,256
	Capital expenditures	$	58		$	2		$	2		$	62
	Nine Months Ended September 30, 2013
	Research and development revenue	$	16,288		$	-		$	-		$	16,288
	Product royalty revenue		37,271			-			-			37,271
	Product sales revenue		277			37			10,680			10,994
	Co-promotion revenue		61			-			-			61
	Contract and collaboration revenue		424			34			32			490
Total revenues		54,321			71			10,712			65,104
Cost of goods sold		3,465			12			5,980			9,457
Research and development expenses		6,446			4,307			3,775			14,528
Depreciation and amortization		543			548			26			1,117
Other operating expenses		27,368			3,374			2,743			33,485
Income (loss) from operations		16,499			(8,170	)		(1,812	)		6,517
Interest income		54			8			1			63
Interest expense		-			(1,326	)		(123	)		(1,449	)
Other non-operating income (expense), net		(9	)		(169	)		2,381			2,203
Income (loss) before income taxes	$	16,544		$	(9,657	)	$	447		$	7,334
Capital expenditures	$	40		$	110		$	3		$	153

Note_14_Subsequent_Events

Note 14 - Subsequent Events	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	14.      Subsequent Events
	On October 9, 2014, the Company and Takeda executed amendments to the Takeda Agreement as well as to the ancillary agreements which, in part, extended the term of the Takeda Agreement beyond December 2020. During the extended term, Takeda and the Company will share the profits of the branded AMITIZA products. Also, beginning in April 2015, Takeda will no longer reimburse the Company for the product details performed by the Company’s sales force or for promotional materials used by the sales force. As a result, the Company will not use a sales force to promote AMITIZA after the end of 2014.
	Also on October 9, 2014, the Company and its affiliate, Sucampo AG, or SAG, (collectively, the Company), along with R-Tech, Takeda and certain affiliates of Takeda (collectively, Takeda Pharmaceutical) executed a settlement and license agreement, (Settlement and License Agreement) with Anchen Pharmaceuticals, Inc., Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc. (collectively, Par) that resolves patent litigation in the United States related to the Company’s AMITIZA (lubiprostone) 8 mcg soft gelatin capsule and 24 mcg soft gelatin capsule product. Under the terms of the Settlement and License Agreement, the Company and R-Tech will grant Par a non-exclusive license to market Par’s generic version of lubiprostone 8 mcg soft gelatin capsule and 24 mcg soft gelatin capsule (collectively, the licensed products) in the U.S. for the indications approved for AMITZA beginning on January 1, 2021, or earlier under certain circumstances.  Also beginning on January 1, 2021, Par will share with the Company the gross profits of the licensed products sold during the term of the Settlement and License Agreement, which continues until each of the Company’s patents has expired.  In the event Par elects to launch an authorized generic product, the Company will supply Par with the product under the terms of a manufacturing and supply agreement at a negotiated price.  Additionally, the Company, R-Tech, Takeda Pharmaceutical, and Par have agreed to dismiss with prejudice the patent litigation filed against Par in the U.S. District Court for the District of Delaware.
	On October 17, 2014, SAG and Takeda’s affiliate, Takeda Pharmaceuticals International GmbH Limited, entered into an exclusive global license agreement (Global License Agreement) to develop and commercialize AMITIZA. The territories excluded from the Global License Agreement are Canada, the United States, Japan and the People’s Republic of China. Canada and the U.S. are covered by the Takeda Agreement, and Japan is covered by the Abbott Agreement. The Global License Agreement is effective until it expires on a country-by-country basis on the fourteenth (14th) anniversary of the date of first commercial sale in that country. Under the terms of the Global License Agreement, SAG will receive a nonrefundable upfront payment of $14 million from Takeda for exclusive rights to develop and commercialize AMITIZA in the global markets covered by the Global License Agreement. In addition, SAG will also be eligible for up to $35 million in additional commercial milestone payments contingent on the achievement of certain net sales revenue targets. Takeda will be responsible for all development activities and costs, with SAG assuming responsibility for the first $6 million in development expenses incurred by Takeda. SAG will supply Takeda with AMITIZA at a negotiated supply price. In addition, Takeda will become the marketing authorization holder and will be responsible for all commercialization and regulatory activities for AMITIZA in the territories covered by the Global License Agreement.
	On October 21, 2014, the Compensation Committee of the Board of Directors approved a revision to the employment agreements applicable to certain executive officers.  The revision to the employment agreements changes the amount of the lump sum payment to such executive officers in the event the Company terminates the executive officer's employment by not renewing the employment agreement or without cause from six (6) months to twelve (12) months of then current base salary and in the event that the executive officer is terminated other than for cause or terminates for good reason within twelve (12) months following the occurrence of a change in control of the Company as the result of a change in control from twelve (12) months to eighteen (18) months of then current annual base salary. On November 4, 2014, the Company and Mr. Andrew Smith entered into a revision to the employment agreement of Mr. Andrew Smith, the principal accounting officer, which changed the amount of the lump sum payment to Mr. Smith in the event the Company terminates Mr. Smith's employment by not renewing the employment agreement or without cause from thirty (30) days to six (6) months of then current base salary and in the event that the executive officer is terminated other than for cause or terminates for good reason within twelve (12) months following the occurrence of a change in control of the Company as the result of a change in control to twelve (12) months of then current annual base salary. This revision had been previously approved by the Compensation Committee of the Board of Directors but had not been finalized or executed by the Company and Mr. Smith.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	Basis of Presentation
	The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and the rules and regulations of the U.S. Securities and Exchange Commission, or SEC, for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company’s Consolidated Financial Statements as of and for the year ended December 31, 2013 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on March 12, 2014. The financial information as of September 30, 2014 and for the three and nine months ended September 30, 2014 and September 30, 2013 is unaudited. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. In the opinion of the Company’s management, all adjustments, consisting only of normal recurring adjustments or accruals, considered necessary for a fair statement of the results of these interim periods have been included. The results of the Company’s operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year.
	The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries: Sucampo AG (SAG) based in Zug, Switzerland, through which the Company conducts certain of its worldwide and European operations; Sucampo Pharma, Ltd. (SPL) based in Tokyo and Osaka, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, (SPA) based in Bethesda, Maryland, through which the Company conducts its North and South American operations; and Sucampo Pharma Europe, Ltd., (SPE) based in Oxford, United Kingdom. The Company liquidated Ambrent Investments S.à.r.l., based in Luxembourg, at the end of 2013. All significant inter-company balances and transactions have been eliminated.
	The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recent Accounting Pronouncements
	In April 2014, the Financial Accounting Standards Board (the FASB) issued Accounting Standards Update 2014-08, “Presentation of Financial Statements and Property, Plant and Equipment”. Under the new standard, only disposals representing a strategic shift in operations that have a major effect on the organization's operations and financial results, or a business activity classified as held for sale, should be presented as discontinued operations. Additionally, it expands the disclosure requirements for discontinued operations to provide more information regarding the assets, liabilities, income and expenses of discontinued operations. This update is effective for interim and annual periods beginning after December 15, 2014, and early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company's consolidated financial statements.
	In May 2014, the FASB issued Accounting Standards Update 2014-09, "Revenue from Contracts with Customers." While the standard supersedes existing revenue recognition guidance, it closely aligns with current GAAP. Under the new standard, revenue is recognized at the time a good or service is transferred to a customer for the amount of consideration received for that specific good or service. It is effective for annual reporting periods beginning after December 15, 2016, including interim reporting periods, and early adoption is not permitted. Entities may use a full retrospective approach or report the cumulative effect as of the date of adoption. The Company is currently evaluating the impact the adoption of this standard will have on the Company’s consolidated financial statements.
	In August 2014, the FASB issued Accounting Standards Update 2014-15, “Presentation of Financial Statements-Going Concern”. The new standard provides guidance regarding management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures. The new standard is effective for annual reporting periods beginning after December 15, 2016, including interim reporting periods, and early adoption is permitted. The Company is currently evaluating the impact of adopting this standard, but does not expect it will have a material impact on the Company’s consolidated financial statements.
Error Corrections and Prior Period Adjustments, Policy [Policy Text Block]	'
	Revision to Previously Issued Financial Statements
	While preparing historical financial statements for the year ended December 31, 2013 and periods ended March 31, 2014 and June 2014, the Company identified certain immaterial errors in the presentation of certain line items in the previously reported financial statements. In accordance with ASC Topic 250, Accounting Changes and Error Corrections, ASC Topic 250-10-S99-1, Assessing Materiality, and ASC Topic 250-10-S99-2, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements, the Company evaluated these errors and, based on an analysis of quantitative and qualitative factors, determined that they were not material, individually or in aggregate to any previously issued financial statements and, therefore, amendment of previously filed reports with the SEC was not required.
	The Company has revised certain comparative periods to correct for these errors; however, certain account balances have not yet been revised. As a result, the Company is including herein the correction of all such immaterial errors that have not been revised in its previous periodic filings. The Company has revised the Condensed Consolidated Statements of Operations and Comprehensive Income for the three and nine months ended September 30, 2013 to correct errors in the presentation of gross profit.  As a result of this revision, gross profit was removed as a sub-total and costs of goods sold was disclosed as an operating cost under the heading “Costs and expenses”. Gross profit was presented on the Condensed Consolidated Statements of Operations and Comprehensive Income beginning in the year ended December 31, 2012 and for periods ended March 31, June 30 and September 30, 2013.
	In addition, the Company has revised the Consolidated Statements of Operations and Comprehensive Income for the year ended December 31, 2013 and 2012, the three months ended March 31, 2013 and March 31, 2014, the three and nine months ended September 30, 2013 and the Consolidated Balance Sheet as of December 31, 2013 and 2012 to correct errors in the recognition of indirect taxes at its Swiss subsidiary. The errors affect the years ended December 31, 2012 and 2013 and the periods ended March 31, 2013, June 30, 2013, September 30, 2013 and March 31, 2014. During those periods, the Company overstated its indirect tax liability and understated net income.
	The Company has also revised the Consolidated Statements of Cash Flows for the year ended December 31, 2013 and the nine months ended September 30, 2013 to correct errors in the classification of foreign exchange gains and losses in net cash used in operating activities, investing activities and the effect of exchange rates on cash and cash equivalents and the change in net income. The errors in classification affect the year ended December 31, 2013 and the periods ended September 30, 2013, June 30, 2013 and March 31, 2013. These errors have no effect on the balances of cash and cash equivalents.
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Restricted Cash
	Restricted cash primarily represents collateral pledged to support a loan agreement with The Bank of Tokyo-Mitsubishi UFJ, Ltd., or the Tokyo-Mitsubishi Bank; a loan agreement with The Mizuho Bank, Ltd., or the Mizuho Bank; a loan agreement between Numab AG, or Numab, and Zurcher Kantonalbank, or the Numab Loan, under which the Company serves as guarantor; and operating leases with certain financial institutions. Restricted cash totaled approximately $28.4 million at September 30, 2014 and $28.6 million at December 31, 2013.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	'
	Certain Risks, Concentrations and Uncertainties
	Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents, restricted cash, investments and receivables. The Company places its cash, cash equivalents and restricted cash with highly rated financial institutions and invests its excess cash in highly rated investments. As of September 30, 2014 and December 31, 2013, approximately $21.2 million, or 19.9%, and $16.4 million, or 17.1%, respectively, of the Company’s cash, cash equivalents, restricted cash and investments were issued or insured by the United States government or United States government agencies. The Company has not experienced any losses on these accounts related to amounts in excess of insured limits.
	Revenues from Takeda, an unrelated party, accounted for 62.4% and 73.9% of the Company’s total revenues for the three months ended September 30, 2014 and 2013, respectively, and 66.7% and 82.9% for the nine months ended September 30, 2014 and 2013, respectively. Accounts receivable, unbilled accounts receivable and product royalties receivable from Takeda accounted for 72.4% and 88.2% of the Company’s total accounts receivable, unbilled accounts receivable and product royalties receivable at September 30, 2014 and December 31, 2013, respectively.
	Revenues from another unrelated party, Abbott, accounted for 36.2% and 24.5% of the Company’s total revenues for the three months ended September 30, 2014 and 2013, respectively, and 31.8% and 16.4% for the nine months ended September 30, 2014 and 2013, respectively.
	The Company depends significantly upon its collaborations with Takeda and Abbott, and its revenues may be adversely impacted if these relationships are disrupted.
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair Value of Financial Instruments
	The carrying amounts of the Company’s financial instruments approximate their fair values based on their short maturities, independent valuations or internal assessments. The Company’s financial instruments include cash and cash equivalents, restricted cash, current and non-current investments, receivables, accounts payable and accrued expenses. The carrying amounts of the notes payable at September 30, 2014 and December 31, 2013 were less than the estimated fair values (see Note 9 below).
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	'
	Accounts Receivable and Unbilled Accounts Receivable
	The Company’s allowance for doubtful accounts related to certain disputed Takeda invoices totaled approximately $796,000 and $440,000 as of September 30, 2014 and December 31, 2013, respectively.

Note_1_Business_Organization_a1

Note 1 - Business Organization and Basis of Presentation (Tables)	9 Months Ended
	Sep. 30, 2014										Sep. 30, 2013
Disclosure Text Block [Abstract]	'										'
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]	'										'
	Selected Items - Annual	As			Revision			As Revised				As Previously Reported						Revision Adjustment						As Revised
		Previously			Adjustment						Condensed Consolidated Statements of Operations	Three			Nine			Three			Nine			Three			Nine
		Reported									and Comprehensive Income	Months			Months			Months			Months			Months			Months
												Ended			Ended			Ended			Ended			Ended			Ended
	Consolidated Balance Sheet										(In thousands, except per share data)	30-Sep-13
	(In thousands)	Presentation as of December 31, 2012									Gross profit	$	14,896		$	55,647		$	(14,896	)	$	(55,647	)	$	0		$	0
	Other liabilities	$	1,253		$	(225	)	$	1,028		Total costs and expenses		(15,940	)		(49,130	)		(6,267	)		(9,457	)		(22,207	)		(58,587	)
	Total liabilities		84,766			(225	)		84,541		Other income (expense), net		(49	)		1,776			232			427			183			2,203
	Accumulated deficit		(34,100	)		225			(33,875	)	Total non-operating income (expense), net		(490	)		390			232			427			(258	)		817
	Total stockholders' equity		43,030			225			43,255		Income (loss) before income taxes		(1,534	)		6,907			232			427			(1,302	)		7,334
	Consolidated Statements of Operations										Net income		1,291			4,266			232			427			1,523			4,693
	and Comprehensive Income										Net income per share: Basic		0.03			0.1			0.01			0.01			0.04			0.11
	(In thousands)	Presentation as of the year ended December 31, 2012									Net income per share: Diluted		0.03			0.1			0.01			0.01			0.04			0.11
	Other income (expense), net	$	1,602		$	225		$	1,827		Comprehensive income		1,056			3,863			232			427			1,288			4,290
	Total non-operating income (expense), net		(565	)		225			(340	)
	Income (loss) before income taxes		7,752			225			7,977
	Net income		4,836			225			5,061
	Comprehensive income		3,148			225			3,373
	Consolidated Statements of Operations
	and Comprehensive Income
	(In thousands, except per share data)	Presentation as of the year ended December 31, 2013
	Other income (expense), net	$	2,921		$	596		$	3,517
	Total non-operating income (expense), net		1,151			596			1,747
	Income (loss) before income taxes		10,347			596			10,943
	Net income		6,419			596			7,015
	Net income per share: Basic		0.15			0.02			0.17
	Net income per share: Diluted		0.15			0.01			0.16
	Comprehensive income		5,854			596			6,450
	Consolidated Statements of Cash Flows
	(In thousands)	Presentation as of the year ended December 31, 2013
	Net cash provided by (used in) operating activities	$	(5,418	)	$	1,209		$	(4,209	)
	Net cash provided by (used in) investing activities		(13,881	)		1,265			(12,616	)
	Effect of exchange rates on cash and cash equivalents		798			(2,474	)		(1,676	)
	Selected Items - Quarterly	As			Revision			As Revised
		Previously			Adjustment
		Reported
	Consolidated Balance Sheet
	(In thousands)	Presentation as of March 31, 2014
	Other Assets	$	455		$	28		$	483
	Other liabilities		1,596			(917	)		679
	Total liabilities		78,839			(917	)		77,922
	Accumulated deficit		(27,006	)		945			(26,061	)
	Total stockholders' equity		65,406			945			66,351
	Consolidated Statements of Operations
	and Comprehensive Income
	(In thousands)	Presentation as of the three months ended March 31, 2014
	Other income (expense), net	$	(323	)	$	124		$	(199	)
	Total non-operating income (expense), net		(666	)		124			(542	)
	Income (loss) before income taxes		1,939			124			2,063
	Income tax benefit (provision)		(1,264	)		(44	)		(1,308	)
	Net income		675			80			755
	Comprehensive income		564			80			644
	Consolidated Balance Sheet
	(In thousands)	Presentation as of March 31, 2013
	Other liabilities	$	1,210		$	(293	)	$	917
	Total liabilities		93,348			(293	)		93,055
	Accumulated deficit		(37,245	)		293			(36,952	)
	Total stockholders' equity		40,003			293			40,296
	Consolidated Statements of Operations
	and Comprehensive Income
	(In thousands, except per share data)	Presentation as of the three months ended March 31, 2013
	Other income (expense), net	$	1,081		$	69		$	1,150
	Total non-operating income (expense), net		605			69			674
Income (loss) before income taxes		(2,003	)		69			(1,934	)
Net income		(3,145	)		69			(3,076	)
Net income per share: Basic		(0.08	)		0.01			(0.07	)
Net income per share: Diluted		(0.08	)		0.01			(0.07	)
Comprehensive income		(3,108	)		69			(3,039	)
Selected Items - Quarterly	As			Revision			As Revised
	Previously			Adjustment
	Reported
Consolidated Balance Sheet
(In thousands)	Presentation as of September 30, 2013
Other liabilities	$	1,296		$	(651	)	$	645
Total liabilities		79,923			(651	)		79,272
Accumulated deficit		(29,834	)		651			(29,183	)
Total stockholders' equity		49,797			651			50,448
Condensed Consolidated Statements of Cash Flows
(In thousands)	Presentation as of the nine months ended September 30, 2013
Net cash provided by (used in) operating activities	$	(8,178	)	$	985		$	(7,193	)
Net cash provided by (used in) investing activities		(12,334	)		470			(11,864	)
Effect of exchange rates on cash and cash equivalents		(2	)		(1,455	)		(1,457	)
Condensed Consolidated Statements of Operations
and Comprehensive Income
(In thousands, except per share data)	Presentation as of the three months ended December 31, 2013
Net Income (loss)	$	2,153		$	170		$	2,323
Net income per share: Basic		0.05			0.01			0.06
Condensed Consolidated Statements of Operations
and Comprehensive Income
(In thousands, except per share data)	Presentation as of the three months ended December 31, 2012
Net Income (loss)	$	13,532		$	225		$	13,757
Net income per share: Diluted		0.32			0.01			0.33

Note_3_Net_Income_Per_Share_Ta

Note 3 - Net Income Per Share (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
		Three Months Ended September 30,				Nine Months Ended September 30,
	(In thousands, except per share data)	2014		2013		2014		2013
	Basic net income per share:
	Net income	$	1,480	$	1,523	$	3,846	$	4,693
	Weighted average class A common shares outstanding		43,796		41,863		43,613		41,644
	Basic net income per share	$	0.03	$	0.04	$	0.09	$	0.11
	Diluted net income per share:
	Net income	$	1,480	$	1,523	$	3,846	$	4,693
	Weighted average class A common shares outstanding		43,796		41,863		43,613		41,644
	Assumed exercise of stock options under the treasury stock method		-		924		-		1,018
			43,796		42,787		43,613		42,662
	Diluted net income per share	$	0.03	$	0.04	$	0.09	$	0.11
Schedule of Potentially Dilutive Securities [Table Text Block]	'
		Three Months Ended September 30,				Nine Months Ended September 30,
	(In thousands)	2014		2013		2014		2013
	Employee stock options		1,759		576		438		576

Note_4_Current_and_NonCurrent_1

Note 4 - Current and Non-Current Investments (Tables)	9 Months Ended
	Sep. 30, 2014
Investments Schedule [Abstract]	'
Available-for-sale Securities [Table Text Block]	'
		30-Sep-14
	(In thousands)	Cost		Unrealized		Unrealized			Fair Value
				Gains		Losses
	Current:
	Commercial paper	$	400	$	-	$	-		$	400
	U.S. government agencies		4,205		2		-			4,207
	Certificates of deposits		4,250		-		-			4,250
	Total	$	8,855	$	2	$	-		$	8,857
	Non-current:
	U.S. government agencies	$	8,055	$	-	$	(24	)	$	8,031
	Certificates of deposit		4,000		-		-			4,000
	Corporate bonds		1,018		-		(3	)		1,015
	Total	$	13,073	$	-	$	(27	)	$	13,046
		31-Dec-13
	(In thousands)	Cost		Unrealized		Unrealized			Fair Value
				Gains		Losses
	Current:
	U.S. government securities	$	1,000	$	-	$	-		$	1,000
	U.S. government agencies		9,048		3		-			9,051
	Certificates of deposit		3,500		-		-			3,500
	Corporate bonds		752		-		-			752
	Municipal securities		1,700		-		-			1,700
	Total	$	16,000	$	3	$	-		$	16,003
	Non-current:
	U.S. government agencies	$	4,212	$	-	$	(3	)	$	4,209
	Certificates of deposits		2,500		-		-			2,500
	Corporate bonds		511		-		(1	)		510
	Total	$	7,223	$	-	$	(4	)	$	7,219
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	'
		Fair Value Measurements at Reporting Date Using
	(In thousands)	Quoted Prices		Significant		Significant			Total
		in Active		Other		Unobservable
		Markets for		Observable		Inputs
		Identical		Inputs		(Level 3)
		Assets		(Level 2)
		(Level 1)
	Commercial paper	$	-	$	8,499	$	-		$	8,499
	U.S. government agencies		-		12,239		-			12,239
	Certificates of deposit		-		8,250		-			8,250
	Corporate bonds		-		3,622		-			3,622
	Money market funds		7,573		-		-			7,573
	Total assets measured at fair value	$	7,573	$	32,610	$	-		$	40,183
		Fair Value Measurements at Reporting Date Using
	(In thousands)	Quoted Prices		Significant		Significant			Total
		in Active		Other		Unobservable
		Markets for		Observable		Inputs
		Identical Assets		Inputs		(Level 3)
		(Level 1)		(Level 2)
	U.S. government securities	$	-	$	1,000	$	-		$	1,000
	U.S. government agencies		-		13,260		-			13,260
	U.S. commercial paper		-		6,449		-			6,449
	Municipal securities		-		1,700		-			1,700
	Certificates of deposit		-		6,000		-			6,000
	Corporate bonds		-		5,533		-			5,533
	Money market funds		5,955		-		-			5,955
	Total assets measured at fair value	$	5,955	$	33,942	$	-		$	39,897

Note_6_Accrued_Expenses_Tables

Note 6 - Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
	(In thousands)	September 30,		December 31,
		2014		2013
	Research and development costs	$	2,826	$	1,775
	Employee compensation		2,488		2,531
	Selling and marketing costs		305		584
	Legal service fees		983		14
	Other accrued expenses		558		778
	Total	$	7,160	$	5,682

Note_7_Commitments_Tables

Note 7 - Commitments (Tables)	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	(In thousands of U.S. dollars)	September 30,
		2014
	2014	$	354
	2015		1,258
	2016		1,290
	2017		345
	2018		204
	Total minimum lease payments	$	3,451

Note_8_Related_Party_Transacti1

Note 8 - Related Party Transactions (Tables)	9 Months Ended
	Sep. 30, 2014
Note 8 - Related Party Transactions (Tables) [Line Items]	'
Schedule of Related Party Transactions [Table Text Block]	'
		Three Months Ended September 30,				Nine Months Ended September 30,
	(In thousands)	2014		2013		2014		2013
	Clinical supplies	$	88	$	35	$	254	$	255
	Other research and development services		139		75		170		181
	Commercial supplies		4,507		3,173		12,133		7,906
		$	4,734	$	3,283	$	12,557	$	8,342
Deferred Revenue [Member]	'
Note 8 - Related Party Transactions (Tables) [Line Items]	'
Schedule of Related Party Transactions [Table Text Block]	'
	(In thousands)	September 30,		December 31,
		2014		2013
	Deferred revenue, current	$	369	$	477
	Deferred revenue, non-current		4,473		4,925
		$	4,842	$	5,402

Note_9_Notes_Payable_Tables

Note 9 - Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Schedule of Debt [Table Text Block]	'
		Fair Value				Carrying Value
	(In thousands)	September 30,		December 31,		September 30,		December 31,
		2014		2013		2014		2013
	Loan agreements	$	18,276	$	19,008	$	18,276	$	19,008
	Promissory notes, Sellers of SAG		30,984		34,889		29,807		33,712
		$	49,260	$	53,897	$	48,083	$	52,720
	Notes payable, current					$	26,342	$	26,892
	Notes payable, non-current						21,741		25,828
						$	48,083	$	52,720

Note_10_Collaboration_and_Lice1

Note 10 - Collaboration and License Agreements (Tables)	9 Months Ended
	Sep. 30, 2014
Abbott [Member]	'
Note 10 - Collaboration and License Agreements (Tables) [Line Items]	'
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	'
	(In thousands)	Amount		Cash Received		Revenue		Change in Accounts		Foreign			Amount
		Deferred at		for the Nine		Recognized for		Receivable for the		Currency Effects			Deferred at
		December 31,		Months Ended		the Nine		Nine Months Ended		for the Nine			September 30,
		2013		September 30,		Months Ended		September 30,		Months Ended			2014
				2014		September 30,		2014		September 30,
						2014				2014
	Collaboration revenue:
	Up-front payment associated with the Company's obligation to participate in joint committees	$	555	$	-	$	30	$	-	$	(20	)	$	505
	Product sales revenue	$	-	$	20,775	$	22,206	$	1,824	$	(393	)	$	-
	Product sales milestone	$	-	$	-	$	2,500	$	2,500	$	-		$	-
Takeda [Member]	'
Note 10 - Collaboration and License Agreements (Tables) [Line Items]	'
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	'
	(In thousands)	Amount		Cash Received		Revenue		Change in Accounts		Amount
		Deferred at		for the Nine		Recognized for		Receivable for the		Deferred at
		December 31,		Months Ended		the Nine		Nine Months Ended		September 30,
		2013		September 30,		Months Ended		September 30,		2014
				2014		September 30,		2014*
						2014
	Collaboration revenue:
	Up-front payment associated with participate in joint committees	$	1,029	$	-	$	73	$	-	$	956
	Research and development revenue:
	Reimbursement of research and development expenses	$	419	$	7,200	$	5,281	$	112	$	2,450
	Product royalty revenue	$	-	$	42,218	$	44,200	$	1,982	$	-
	Co-promotion revenue	$	-	$	1,381	$	2,021	$	640	$	-

Note_11_Stock_Option_Plans_Tab

Note 11 - Stock Option Plans (Tables)	9 Months Ended
	Sep. 30, 2014
Stockholders' Equity Note [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
		Shares			Weighted		Weighted		Aggregate
					Average		Average		Intrinsic Value
					Exercise Price		Remaining
					Per Share		Contractual
							Term (Years)
	Options outstanding, December 31, 2013		146,200		$	10
	Options expired		(25,500	)		10
	Options outstanding, September 30, 2014		120,700			10		1.59	$	-
	Options exercisable, September 30, 2014		120,700			10		1.59	$	-
		Shares			Weighted		Weighted		Aggregate
					Average		Average		Intrinsic Value
					Exercise Price		Remaining
					Per Share		Contractual
							Term (Years)
	Options outstanding, December 31, 2013		2,513,063		$	5.03
	Options granted		1,861,745			7.29
	Options exercised		(405,140	)		4.36
	Options forfeited		(209,493	)		4.59
	Options expired		(193,275	)		4.81
	Options outstanding, September 30, 2014		3,566,900			6.33		8.42	$	3,085,216
	Options exercisable, September 30, 2014		958,582			5.93		6.35	$	1,402,961
		Shares			Weighted		Weighted		Aggregate
					Average		Average		Intrinsic Value
					Exercise Price		Remaining
					Per Share		Contractual
							Term (Years)
	Options outstanding, December 31, 2013		410,000		$	5.85
	Options exercised		(67,500	)		5.85
	Options outstanding, September 30, 2014		342,500			5.85		0.58	$	222,625
	Options exercisable, September 30, 2014		342,500			5.85		0.58	$	222,625

Note_13_Segment_Reporting_Tabl

Note 13 - Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	(In thousands)	Americas			Europe			Asia			Consolidated
	Three Months Ended September 30, 2014
	Research and development revenue	$	1,797		$	-		$	-		$	1,797
	Product royalty revenue		16,811			-			-			16,811
	Product sales revenue		170			142			11,405			11,717
	Co-promotion revenue		936			-			-			936
	Contract and collaboration revenue		141			51			10			202
	Total revenues		19,855			193			11,415			31,463
	Costs of goods sold		79			318			4,577			4,974
	Intangible assets impairment		1,502			4,129			-			5,631
	Research and development expenses		2,733			1,893			671			5,297
	Depreciation and amortization		140			116			7			263
	Other operating expenses		8,626			2,630			399			11,655
	Income (loss) from operations		6,775			(8,893	)		5,761			3,643
	Interest income		24			2			-			26
	Interest expense		(343	)		-			(41	)		(384	)
	Other non-operating income (expense), net		29			(443	)		933			519
	Income (loss) before income taxes	$	6,485		$	(9,334	)	$	6,653		$	3,804
	Capital expenditures	$	13		$	-		$	-		$	13
	Three Months Ended September 30, 2013
	Research and development revenue	$	2,027		$	-		$	-		$	2,027
	Product royalty revenue		13,595			-			-			13,595
	Product sales revenue		170			17			5,191			5,378
	Co-promotion revenue		-			-			-			-
	Contract and collaboration revenue		141			12			10			163
	Total revenues		15,933			29			5,201			21,163
	Costs of goods sold		3,389			4			2,874			6,267
	Research and development expenses		3,860			(305	)		919			4,474
	Depreciation and amortization		309			47			8			364
	Other operating expenses		8,893			1,646			563			11,102
	Income (loss) from operations		(518	)		(1,363	)		837			(1,044	)
	Interest income		18			2			-			20
	Interest expense		-			(417	)		(44	)		(461	)
	Other non-operating income, net		6			95			82			183
	Income (loss) before income taxes	$	(494	)	$	(1,683	)	$	875		$	(1,302	)
	Capital expenditures	$	9		$	4		$	-		$	13
	(In thousands)	Americas			Europe			Asia			Consolidated
	Nine Months Ended September 30, 2014
	Research and development revenue	$	5,281		$	-		$	-		$	5,281
	Product royalty revenue		44,200			-			-			44,200
	Product sales revenue		551			297			24,724			25,572
	Co-promotion revenue		2,021			-			-			2,021
	Contract and collaboration revenue		424			165			30			619
	Total revenues		52,477			462			24,754			77,693
	Cost of goods sold		375			357			11,431			12,163
	Intangible assets impairment		1,502			4,129			-			5,631
	Research and development expenses		7,565			4,528			2,591			14,684
	Depreciation and amortization		514			448			22			984
	Other operating expenses		25,306			7,364			1,378			34,048
	Income (loss) from operations		17,215			(16,364	)		9,332			10,183
	Interest income		67			6			33			106
	Interest expense		(1,054	)		-			(122	)		(1,176	)
	Other non-operating income (expense), net		31			547			(435	)		143
	Income (loss) before income taxes	$	16,259		$	(15,811	)	$	8,808		$	9,256
	Capital expenditures	$	58		$	2		$	2		$	62
	Nine Months Ended September 30, 2013
	Research and development revenue	$	16,288		$	-		$	-		$	16,288
	Product royalty revenue		37,271			-			-			37,271
	Product sales revenue		277			37			10,680			10,994
	Co-promotion revenue		61			-			-			61
	Contract and collaboration revenue		424			34			32			490
	Total revenues		54,321			71			10,712			65,104
	Cost of goods sold		3,465			12			5,980			9,457
Research and development expenses		6,446			4,307			3,775			14,528
Depreciation and amortization		543			548			26			1,117
Other operating expenses		27,368			3,374			2,743			33,485
Income (loss) from operations		16,499			(8,170	)		(1,812	)		6,517
Interest income		54			8			1			63
Interest expense		-			(1,326	)		(123	)		(1,449	)
Other non-operating income (expense), net		(9	)		(169	)		2,381			2,203
Income (loss) before income taxes	$	16,544		$	(9,657	)	$	447		$	7,334
Capital expenditures	$	40		$	110		$	3		$	153

Note_1_Business_Organization_a2

Note 1 - Business Organization and Basis of Presentation (Details)	3 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
	USD ($)	USD ($)	RESCULA [Member]	AMITIZA [Member]	The Abbott Agreement [Member]	The Abbott Agreement [Member]	The Abbott Agreement [Member]
			USD ($)	Takeda [Member]	USD ($)	USD ($)	JPY (¥)
Note 1 - Business Organization and Basis of Presentation (Details) [Line Items]	'	'	'	'	'	'	'
Revenue Recognition, Milestone Method, Revenue to be Recognized	'	'	'	'	'	$2,500,000	'
Revenue Recognition, Milestone Method, Remittance Term	'	'	'	'	'	'45 days	'45 days
Revenue Recognition, Milestone Method, Sales Revenue Milestone (in Yen)	'	'	'	'	'	'	5,000,000,000
Revenue Recognition, Milestone Method, Revenue Recognized	'	'	'	'	2,500,000	37,500,000	'
Impairment of Intangible Assets, Finite-lived	$5,631,000	$5,631,000	$5,600,000	'	'	'	'
Additioinal Reformulation Costs Funded, Percentage	'	'	'	100.00%	'	'	'

Note_1_Business_Organization_a3

Note 1 - Business Organization and Basis of Presentation (Details) - Revision to Previously Issued Financial Statements (USD $)	3 Months Ended						9 Months Ended		12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Other liabilities	$1,512	$679	$1,233	$645	$917	$1,028	$1,512	$645	$1,233	$1,028
Total liabilities	72,962	77,922	77,908	79,272	93,055	84,541	72,962	79,272	77,908	84,541
Accumulated deficit	-23,014	-26,061	-26,860	-29,183	-36,952	-33,875	-23,014	-29,183	-26,860	-33,875
Total stockholders' equity	71,656	66,351	58,969	50,448	40,296	43,255	71,656	50,448	58,969	43,255
Other income (expense), net	519	-199	'	183	1,150	'	143	2,203	3,517	1,827
Total non-operating income (expense), net	161	-542	'	-258	674	'	-927	817	1,747	-340
Income (loss) before income taxes	3,804	2,063	'	-1,302	-1,934	'	9,256	7,334	10,943	7,977
Income tax benefit (provision)	2,324	-1,308	'	-2,825	'	'	5,410	2,641	'	'
Net income	1,480	755	2,323	1,523	-3,076	13,757	3,846	4,693	7,015	5,061
Net income per share: Basic (in Dollars per share)	$0.03	'	$0.06	$0.04	($0.07)	'	$0.09	$0.11	$0.17	'
Net income per share: Diluted (in Dollars per share)	$0.03	'	'	$0.04	($0.07)	$0.33	$0.09	$0.11	$0.16	'
Comprehensive income	1,762	644	'	1,288	-3,039	'	3,888	4,290	6,450	3,373
Net cash provided by (used in) operating activities	'	'	'	'	'	'	7,532	-7,193	-4,209	'
Net cash provided by (used in) investing activities	'	'	'	'	'	'	1,164	-11,864	-12,616	'
Effect of exchange rates on cash and cash equivalents	'	'	'	'	'	'	-226	-1,457	-1,676	'
Other Assets	461	483	488	'	'	'	461	'	488	'
Scenario, Previously Reported [Member]	'	'	'	'	'	'	'	'	'	'
Other liabilities	'	1,596	'	1,296	1,210	1,253	'	1,296	'	1,253
Total liabilities	'	78,839	'	79,923	93,348	84,766	'	79,923	'	84,766
Accumulated deficit	'	-27,006	'	-29,834	-37,245	-34,100	'	-29,834	'	-34,100
Total stockholders' equity	'	65,406	'	49,797	40,003	43,030	'	49,797	'	43,030
Other income (expense), net	'	-323	'	-49	1,081	'	'	1,776	2,921	1,602
Total non-operating income (expense), net	'	-666	'	-490	605	'	'	390	1,151	-565
Income (loss) before income taxes	'	1,939	'	-1,534	-2,003	'	'	6,907	10,347	7,752
Income tax benefit (provision)	'	-1,264	'	'	'	'	'	'	'	'
Net income	'	675	2,153	1,291	-3,145	13,532	'	4,266	6,419	4,836
Net income per share: Basic (in Dollars per share)	'	'	$0.05	$0.03	($0.08)	'	'	$0.10	$0.15	'
Net income per share: Diluted (in Dollars per share)	'	'	'	$0.03	($0.08)	$0.32	'	$0.10	$0.15	'
Comprehensive income	'	564	'	1,056	-3,108	'	'	3,863	5,854	3,148
Net cash provided by (used in) operating activities	'	'	'	'	'	'	'	-8,178	-5,418	'
Net cash provided by (used in) investing activities	'	'	'	'	'	'	'	-12,334	-13,881	'
Effect of exchange rates on cash and cash equivalents	'	'	'	'	'	'	'	-2	798	'
Other Assets	'	455	'	'	'	'	'	'	'	'
Restatement Adjustment [Member]	'	'	'	'	'	'	'	'	'	'
Other liabilities	'	-917	'	-651	-293	-225	'	-651	'	-225
Total liabilities	'	-917	'	-651	-293	-225	'	-651	'	-225
Accumulated deficit	'	945	'	651	293	225	'	651	'	225
Total stockholders' equity	'	945	'	651	293	225	'	651	'	225
Other income (expense), net	'	124	'	232	69	'	'	427	596	225
Total non-operating income (expense), net	'	124	'	232	69	'	'	427	596	225
Income (loss) before income taxes	'	124	'	232	69	'	'	427	596	225
Income tax benefit (provision)	'	-44	'	'	'	'	'	'	'	'
Net income	'	80	170	232	69	225	'	427	596	225
Net income per share: Basic (in Dollars per share)	'	'	$0.01	$0.01	$0.01	'	'	$0.01	$0.02	'
Net income per share: Diluted (in Dollars per share)	'	'	'	$0.01	$0.01	$0.01	'	$0.01	$0.01	'
Comprehensive income	'	80	'	232	69	'	'	427	596	225
Net cash provided by (used in) operating activities	'	'	'	'	'	'	'	985	1,209	'
Net cash provided by (used in) investing activities	'	'	'	'	'	'	'	470	1,265	'
Effect of exchange rates on cash and cash equivalents	'	'	'	'	'	'	'	-1,455	-2,474	'
Other Assets	'	$28	'	'	'	'	'	'	'	'

Note_1_Business_Organization_a4

Note 1 - Business Organization and Basis of Presentation (Details) - Revision to Previously Issued Condensed Consolidated Statements of Operations and Comprehensive Income (USD $)	3 Months Ended						9 Months Ended		12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Gross profit	'	'	'	$0	'	'	'	$0	'	'
Total costs and expenses	-27,820	'	'	-22,207	'	'	-67,510	-58,587	'	'
Other income (expense), net	519	-199	'	183	1,150	'	143	2,203	3,517	1,827
Total non-operating income (expense), net	161	-542	'	-258	674	'	-927	817	1,747	-340
Income (loss) before income taxes	3,804	2,063	'	-1,302	-1,934	'	9,256	7,334	10,943	7,977
Net income	1,480	755	2,323	1,523	-3,076	13,757	3,846	4,693	7,015	5,061
Net income per share: Basic (in Dollars per share)	$0.03	'	$0.06	$0.04	($0.07)	'	$0.09	$0.11	$0.17	'
Net income per share: Diluted (in Dollars per share)	$0.03	'	'	$0.04	($0.07)	$0.33	$0.09	$0.11	$0.16	'
Comprehensive income	1,762	644	'	1,288	-3,039	'	3,888	4,290	6,450	3,373
Scenario, Previously Reported [Member]	'	'	'	'	'	'	'	'	'	'
Gross profit	'	'	'	14,896	'	'	'	55,647	'	'
Total costs and expenses	'	'	'	-15,940	'	'	'	-49,130	'	'
Other income (expense), net	'	-323	'	-49	1,081	'	'	1,776	2,921	1,602
Total non-operating income (expense), net	'	-666	'	-490	605	'	'	390	1,151	-565
Income (loss) before income taxes	'	1,939	'	-1,534	-2,003	'	'	6,907	10,347	7,752
Net income	'	675	2,153	1,291	-3,145	13,532	'	4,266	6,419	4,836
Net income per share: Basic (in Dollars per share)	'	'	$0.05	$0.03	($0.08)	'	'	$0.10	$0.15	'
Net income per share: Diluted (in Dollars per share)	'	'	'	$0.03	($0.08)	$0.32	'	$0.10	$0.15	'
Comprehensive income	'	564	'	1,056	-3,108	'	'	3,863	5,854	3,148
Restatement Adjustment [Member]	'	'	'	'	'	'	'	'	'	'
Gross profit	'	'	'	-14,896	'	'	'	-55,647	'	'
Total costs and expenses	'	'	'	-6,267	'	'	'	-9,457	'	'
Other income (expense), net	'	124	'	232	69	'	'	427	596	225
Total non-operating income (expense), net	'	124	'	232	69	'	'	427	596	225
Income (loss) before income taxes	'	124	'	232	69	'	'	427	596	225
Net income	'	80	170	232	69	225	'	427	596	225
Net income per share: Basic (in Dollars per share)	'	'	$0.01	$0.01	$0.01	'	'	$0.01	$0.02	'
Net income per share: Diluted (in Dollars per share)	'	'	'	$0.01	$0.01	$0.01	'	$0.01	$0.01	'
Comprehensive income	'	$80	'	$232	$69	'	'	$427	$596	$225

Note_2_Summary_of_Significant_1

Note 2 - Summary of Significant Accounting Policies (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Abbott [Member]

Abbott [Member]

Abbott [Member]

Abbott [Member]

Sales Revenue, Goods, Net [Member]

Sales Revenue, Goods, Net [Member]

Sales Revenue, Goods, Net [Member]

Sales Revenue, Goods, Net [Member]

Accounts Receivable, Unbilled Accounts Receivable and Product Royalties Receivable [Member]

Accounts Receivable, Unbilled Accounts Receivable and Product Royalties Receivable [Member]

Sales Revenue, Goods, Net [Member]

Sales Revenue, Goods, Net [Member]

Sales Revenue, Goods, Net [Member]

Sales Revenue, Goods, Net [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted Cash and Cash Equivalents (in Dollars)

$28,400,000

$28,600,000

'

'

'

'

'

'

'

'

'

'

'

Cash, FDIC Insured Amount (in Dollars)

21,200,000

16,400,000

'

'

'

'

'

'

'

'

'

'

'

PercentageOfDepositWithinFederallyInsuredLimits

19.90%

17.10%

'

'

'

'

'

'

'

'

'

'

'

Concentration Risk, Percentage

'

'

'

62.40%

73.90%

66.70%

82.90%

72.40%

88.20%

36.20%

24.50%

31.80%

16.40%

Allowance for Doubtful Accounts Receivable (in Dollars)

$796,000

'

$440,000

'

'

'

'

'

'

'

'

'

'

Note_3_Net_Income_Per_Share_De

Note 3 - Net Income Per Share (Details) - Net Income (Loss) per Share (USD $)	3 Months Ended						9 Months Ended		12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Basic net income per share:	'	'	'	'	'	'	'	'	'	'
Net income (in Dollars)	$1,480	$755	$2,323	$1,523	($3,076)	$13,757	$3,846	$4,693	$7,015	$5,061
Weighted average class A common shares outstanding	43,796	'	'	41,863	'	'	43,613	41,644	'	'
Assumed exercise of stock options under the treasury stock method	'	'	'	924	'	'	'	1,018	'	'
	43,796	'	'	42,787	'	'	43,613	42,662	'	'
Diluted net income per share (in Dollars per share)	$0.03	'	'	$0.04	($0.07)	$0.33	$0.09	$0.11	$0.16	'
Basic net income per share (in Dollars per share)	$0.03	'	$0.06	$0.04	($0.07)	'	$0.09	$0.11	$0.17	'

Note_3_Net_Income_Per_Share_De1

Note 3 - Net Income Per Share (Details) - Potentially Dilutive Securities	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Note 3 - Net Income Per Share (Details) - Potentially Dilutive Securities [Line Items]	'	'	'	'
Employee stock options	'	924	'	1,018
Employee Stock Option [Member]	'	'	'	'
Note 3 - Net Income Per Share (Details) - Potentially Dilutive Securities [Line Items]	'	'	'	'
Employee stock options	1,759	576	438	576

Note_4_Current_and_NonCurrent_2

Note 4 - Current and Non-Current Investments (Details) - Current and Non-Current Investments (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Commercial Paper [Member] | Current [Member]	'	'
Current:	'	'
Cost	$400	'
Fair value	400	'
US Government Agencies Debt Securities [Member] | Current [Member]	'	'
Current:	'	'
Cost	4,205	9,048
Unrealized gains	2	3
Fair value	4,207	9,051
Certificates of Deposit [Member] | Current [Member]	'	'
Current:	'	'
Cost	4,250	3,500
Fair value	4,250	3,500
Certificates of Deposit [Member] | Non-current [Member]	'	'
Current:	'	'
Cost	4,000	2,500
Fair value	4,000	2,500
US Treasury and Government [Member] | Current [Member]	'	'
Current:	'	'
Cost	'	1,000
Fair value	'	1,000
US Treasury and Government [Member] | Non-current [Member]	'	'
Current:	'	'
Cost	8,055	4,212
Unrealized losses	-24	-3
Fair value	8,031	4,209
Corporate Bond Securities [Member] | Current [Member]	'	'
Current:	'	'
Cost	'	752
Fair value	'	752
Corporate Bond Securities [Member] | Non-current [Member]	'	'
Current:	'	'
Cost	1,018	511
Unrealized losses	-3	-1
Fair value	1,015	510
Municipal Bonds [Member] | Current [Member]	'	'
Current:	'	'
Cost	'	1,700
Fair value	'	1,700
Current [Member]	'	'
Current:	'	'
Cost	8,855	16,000
Unrealized gains	2	3
Fair value	8,857	16,003
Non-current [Member]	'	'
Current:	'	'
Cost	13,073	7,223
Unrealized losses	-27	-4
Fair value	$13,046	$7,219

Note_4_Current_and_NonCurrent_3

Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	$8,499	'
Commercial Paper [Member] | Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	8,499	'
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	12,239	13,260
US Government Agencies Debt Securities [Member] | Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	12,239	13,260
Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	8,250	6,000
Certificates of Deposit [Member] | Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	8,250	6,000
Corporate Bond Securities [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	3,622	5,533
Corporate Bond Securities [Member] | Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	3,622	5,533
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	7,573	5,955
Money Market Funds [Member] | Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	7,573	5,955
US Treasury and Government [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	'	1,000
US Treasury and Government [Member] | Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	'	1,000
Domestic Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	'	6,449
Domestic Corporate Debt Securities [Member] | Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	'	6,449
Municipal Notes [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	'	1,700
Municipal Notes [Member] | Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	'	1,700
Fair Value, Inputs, Level 1 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	7,573	5,955
Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	32,610	33,942
Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	$40,183	$39,897

Note_5_Intangible_Assets_Detai

Note 5 - Intangible Assets (Details) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2013

Apr. 30, 2009

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

RESCULA [Member]

RESCULA [Member]

RESCULA [Member]

RESCULA [Member]

Other Noncurrent Assets [Member]

Other Noncurrent Assets [Member]

2009 R-Tech Agreement [Member]

2009 R-Tech Agreement [Member]

2009 R-Tech Agreement [Member]

2009 R-Tech Agreement [Member]

2009 R-Tech Agreement [Member]

2009 R-Tech Agreement [Member]

2011 R-Tech Agreement [Member]

2011 R-Tech Agreement [Member]

2011 R-Tech Agreement [Member]

2011 R-Tech Agreement [Member]

2011 R-Tech Agreement [Member]

Americas [Member]

Europe [Member]

2009 R-Tech Agreement [Member]

2009 R-Tech Agreement [Member]

Note 5 - Intangible Assets (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment of Intangible Assets (Excluding Goodwill)

'

$1,500,000

$4,100,000

$5,600,000

$0

'

'

'

$4,100,000

'

'

'

'

'

'

'

'

'

Payments to Acquire Intangible Assets

'

'

'

'

'

'

'

3,500,000

'

'

'

'

'

'

'

6,000,000

'

'

Finite-lived Intangible Assets Acquired

'

'

'

'

'

3,400,000

3,400,000

'

'

'

'

'

'

'

'

6,000,000

'

'

Asset Impairment Charges

1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization of Intangible Assets

'

'

'

'

'

'

'

'

85,000

57,000

256,000

227,000

'

102,000

153,000

409,000

460,000

'

Finite-Lived Intangible Assets, Net

'

'

'

'

'

'

'

'

'

'

'

'

$1,800,000

'

'

'

'

$4,400,000

Note_6_Accrued_Expenses_Detail

Note 6 - Accrued Expenses (Details) - Accrued Expenses (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Expenses [Abstract]	'	'
Research and development costs	$2,826	$1,775
Employee compensation	2,488	2,531
Selling and marketing costs	305	584
Legal service fees	983	14
Other accrued expenses	558	778
Total	$7,160	$5,682

Note_7_Commitments_Details

Note 7 - Commitments (Details) (USD $)	3 Months Ended		9 Months Ended			12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Dec. 31, 2013
					Guarantee of Indebtedness of Others [Member]	Guarantee of Indebtedness of Others [Member]
Note 7 - Commitments (Details) [Line Items]	'	'	'	'	'	'
Operating Leases, Rent Expense	$343,000	$323,000	$1,000,000	$1,000,000	'	'
Future Estimated Research and Development Costs	'	'	6,900,000	'	'	'
Loss Contingency, Range of Possible Loss, Maximum	'	'	'	'	2,300,000	'
Loss Contingency, Estimate of Possible Loss	'	'	'	'	2,100,000	'
Loss Contingency Accrual, Provision	'	'	'	'	$1,000,000	$663,000

Note_7_Commitments_Details_Fut

Note 7 - Commitments (Details) - Future Minimum, Non-Cancelable Lease Payments (USD $)	Sep. 30, 2014
In Thousands, unless otherwise specified
Future Minimum, Non-Cancelable Lease Payments [Abstract]	'
2014	$354
2015	1,258
2016	1,290
2017	345
2018	204
Total minimum lease payments	$3,451

Note_8_Related_Party_Transacti2

Note 8 - Related Party Transactions (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2011	Sep. 30, 2014	Sep. 30, 2014
	R-Tech [Member]	R-Tech [Member]	R-Tech [Member]	R-Tech [Member]	Numab [Member]	Numab [Member]	Numab Agreement [Member]	Numab Agreement [Member]	Numab Agreement [Member]
	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)	CHF	Zurcher Kantonalbank [Member]	USD ($)	CHF
							CHF
Note 8 - Related Party Transactions (Details) [Line Items]	'	'	'	'	'	'	'	'	'
Contracts Revenue	$160,000	$105,000	$369,000	$373,000	'	'	'	'	'
Loans Pledged as Collateral	'	'	'	'	'	'	5,000,000	2,300,000	2,200,000
Long-term Debt, Gross	'	'	'	'	$2,100,000	2,000,000	'	'	'

Note_8_Related_Party_Transacti3

Note 8 - Related Party Transactions (Details) - Expenses under Agreements with R-Tech (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Related Party Transaction [Line Items]	'	'	'	'
Expenses related to R-Tech	$4,734	$3,283	$12,557	$8,342
Clinical Supplies [Member]	'	'	'	'
Related Party Transaction [Line Items]	'	'	'	'
Expenses related to R-Tech	88	35	254	255
Other research and development services [Member]	'	'	'	'
Related Party Transaction [Line Items]	'	'	'	'
Expenses related to R-Tech	139	75	170	181
Commercial supplies [Member]	'	'	'	'
Related Party Transaction [Line Items]	'	'	'	'
Expenses related to R-Tech	$4,507	$3,173	$12,133	$7,906

Note_8_Related_Party_Transacti4

Note 8 - Related Party Transactions (Details) - Amounts Included in Deferred Revenue Resulting from Deferral of Upfront Payments Relating to Exclusive Supply Agreements with R-Tech (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Related Party Transaction [Line Items]	'	'
Deferred revenue, current	$2,047	$1,365
Deferred revenue, non-current	5,457	6,169
R-Tech [Member]	'	'
Related Party Transaction [Line Items]	'	'
Deferred revenue, current	369	477
Deferred revenue, non-current	4,473	4,925
	$4,842	$5,402

Note_9_Notes_Payable_Details

Note 9 - Notes Payable (Details)	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013	Nov. 30, 2010	Nov. 30, 2010	Sep. 30, 2014	Dec. 31, 2013	Mar. 31, 2013	Mar. 31, 2013
In Millions, unless otherwise specified	Kuno and Ueno Trust [Member]	Secured Debt [Member]	Secured Debt [Member]	Secured Debt [Member]	Secured Debt [Member]	Secured Debt [Member]	Secured Debt [Member]	Secured Debt [Member]	Secured Debt [Member]
	Subordinated Unsecured Promissory Notes [Member]	Tokyo-Mitsubishi Bank [Member]	Tokyo-Mitsubishi Bank [Member]	Tokyo-Mitsubishi Bank [Member]	Tokyo-Mitsubishi Bank [Member]	Mizuho Bank Limited [Member]	Mizuho Bank Limited [Member]	Mizuho Bank Limited [Member]	Mizuho Bank Limited [Member]
		USD ($)	USD ($)	USD ($)	JPY (¥)	USD ($)	USD ($)	USD ($)	JPY (¥)
Note 9 - Notes Payable (Details) [Line Items]	'	'	'	'	'	'	'	'	'
Line of Credit Facility, Maximum Borrowing Capacity	'	'	'	$11.60	¥ 1,000	'	'	$10.60	¥ 1,000
Line of Credit Facility, Interest Rate at Period End	'	1.21%	'	'	'	'	'	'	'
Long-term Line of Credit	'	9.1	9.5	'	'	9.1	9.5	'	'
Interest-bearing Deposits in Banks and Other Financial Institutions	'	$14.90	'	'	'	$11	'	'	'
Weighted Average Rate Domestic Deposit	'	0.25%	'	'	'	0.30%	'	'	'
Line of Credit Facility, Interest Rate During Period	'	'	'	'	'	0.46%	'	'	'
Debt Instrument, Interest Rate, Stated Percentage	4.32%	'	'	'	'	'	'	'	'

Note_9_Notes_Payable_Details_N

Note 9 - Notes Payable (Details) - Notes Payable (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Note 9 - Notes Payable (Details) - Notes Payable [Line Items]	'	'
Note Payable Fair Value	$49,260	$53,897
Note Payable Carrying Value	48,083	52,720
Notes payable, current	26,342	26,892
Notes payable, non-current	21,741	25,828
Mizuho Bank Limited [Member]	'	'
Note 9 - Notes Payable (Details) - Notes Payable [Line Items]	'	'
Note Payable Fair Value	18,276	19,008
Note Payable Carrying Value	18,276	19,008
SAG [Member]	'	'
Note 9 - Notes Payable (Details) - Notes Payable [Line Items]	'	'
Note Payable Fair Value	30,984	34,889
Note Payable Carrying Value	$29,807	$33,712

Note_10_Collaboration_and_Lice2

Note 10 - Collaboration and License Agreements (Details)	3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
	The Abbott Agreement [Member]	The Abbott Agreement [Member]	The Abbott Agreement [Member]	The Takeda Agreement [Member]
	USD ($)	USD ($)	JPY (¥)	USD ($)
Note 10 - Collaboration and License Agreements (Details) [Line Items]	'	'	'	'
Revenue Recognition, Milestone Method, Revenue Recognized	$2,500,000	$37,500,000	'	$160,000,000
Revenue Recognition, Milestone Method, Sales Revenue Milestone (in Yen)	'	'	¥ 5,000,000,000	'

Note_10_Collaboration_and_Lice3

Note 10 - Collaboration and License Agreements (Details) - Cash Streams and Related Revenue Recognized or Deferred under Abbott Agreement (Abbott [Member], USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Collaborative Arrangement [Member]	'	'
Deferred Revenue Arrangement [Line Items]	'	'
Amount Deferred	$505	$555
Revenue Recognized	30	'
Foreign Currency Effects	-20	'
Product Sales Revenue [Member]	'	'
Deferred Revenue Arrangement [Line Items]	'	'
Cash Received	20,775	'
Revenue Recognized	22,206	'
Accounts Receivable	1,824	'
Foreign Currency Effects	-393	'
Product Sales Milestone [Member]	'	'
Deferred Revenue Arrangement [Line Items]	'	'
Revenue Recognized	2,500	'
Accounts Receivable	$2,500	'

Note_10_Collaboration_and_Lice4

Note 10 - Collaboration and License Agreements (Details) - Cash Streams and Related Revenue Recognized or Deferred under Takeda Agreement (Takeda [Member], USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014		Dec. 31, 2013
Reimbursement Of Research And Development Expenses [Member] | Research and Development Revenue [Member]	'		'
Collaboration revenue:	'		'
Amount Deferred	$2,450		$419
Cash Received	7,200		'
Revenue Recognized	5,281		'
Accounts Receivable	112	[1]	'
Collaborative Arrangement [Member]	'		'
Collaboration revenue:	'		'
Amount Deferred	956		1,029
Revenue Recognized	73		'
Accounts Receivable	'	[1]	'
Product Royalty Revenue [Member]	'		'
Collaboration revenue:	'		'
Cash Received	42,218		'
Revenue Recognized	44,200		'
Accounts Receivable	1,982	[1]	'
Co-promotion revenue [Member]	'		'
Collaboration revenue:	'		'
Cash Received	1,381		'
Revenue Recognized	2,021		'
Accounts Receivable	$640	[1]	'
[1]	Includes billed and unbilled accounts receivable.

Note_11_Stock_Option_Plans_Det

Note 11 - Stock Option Plans (Details) (USD $)	9 Months Ended	12 Months Ended	3 Months Ended		9 Months Ended		3 Months Ended	9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
			Common Class A [Member]	Common Class A [Member]	Common Class A [Member]	Common Class A [Member]	Performance Shares [Member]	Performance Shares [Member]	Accelerated-vesting Stock Options [Member]	Time-Based Stock Options [Member]	Employee Stock Option [Member]
			2006 Employee Stock Purchase Plan [Member]	2006 Employee Stock Purchase Plan [Member]	2006 Employee Stock Purchase Plan [Member]	2006 Employee Stock Purchase Plan [Member]
Note 11 - Stock Option Plans (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	'	'	'	'	'	'	200,000	'	450,000	341,745	'
Investment Options, Exercise Price (in Dollars per share)	'	'	'	'	'	'	$16	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	'	'	'	'	'	'	'4 years	'	'10 years	'10 years	'
Investment Options, Expiration Date	'	'	'	'	'	'	'	30-Jul-28	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'	'	'	'	'	'	'4 years	'4 years	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Portion to Vest	'	'	'	'	'	'	'	'	'one third	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)	$7.29	$7.36	'	'	'	'	'	'	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)	$5,300,000	'	'	'	'	'	'	'	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'	'	'	'	'	'	'	'	'	'	'3 years 116 days
Stock Issued During Period, Value, Employee Stock Purchase Plan (in Dollars)	$23,000	'	$9,670	$6,416	$22,896	$17,411	'	'	'	'	'
Stock Issued During Period, Shares, Employee Stock Purchase Plans	'	'	1,566	1,082	3,555	2,846	'	'	'	'	'

Note_11_Stock_Option_Plans_Det1

Note 11 - Stock Option Plans (Details) - Employee Stock Option Activity (USD $)	9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
2001 Incentive Plan [Member]	'	'
Note 11 - Stock Option Plans (Details) - Employee Stock Option Activity [Line Items]	'	'
Options Outstanding	120,700	146,200
Options Outstanding, Weighted Average Exercise Price Per Share	$10	$10
Options Outstanding, Weighted Average Remaining Contractual Term (Years)	'1 year 215 days	'
Options exercisable	120,700	'
Options exercisable, Weighted Average Exercise Price Per Share	$10	'
Options exercisable, Weighted Average Remaining Contractual Term (Years)	'1 year 215 days	'
Options expired	-25,500	'
Options expired, Weighted Average Exercise Price Per Share	$10	'
Stock Incentive Plan 2006 [Member]	'	'
Note 11 - Stock Option Plans (Details) - Employee Stock Option Activity [Line Items]	'	'
Options Outstanding	3,566,900	2,513,063
Options Outstanding, Weighted Average Exercise Price Per Share	$6.33	$5.03
Options Outstanding, Weighted Average Remaining Contractual Term (Years)	'8 years 153 days	'
Options Outstanding, Aggregate Intrinsic Value	$3,085,216	'
Options granted	1,861,745	'
Options granted	$7.29	'
Options exercised	-405,140	'
Options exercised, Weighted Average Exercise Price Per Share	$4.36	'
Options forfeited	-209,493	'
Options forfeited	$4.59	'
Options exercisable	958,582	'
Options exercisable, Weighted Average Exercise Price Per Share	$5.93	'
Options exercisable, Weighted Average Remaining Contractual Term (Years)	'6 years 127 days	'
Options exercisable, Aggregate Intrinsic Value	1,402,961	'
Options expired	-193,275	'
Options expired, Weighted Average Exercise Price Per Share	$4.81	'
Non Employee Stock Plan 2001 [Member]	'	'
Note 11 - Stock Option Plans (Details) - Employee Stock Option Activity [Line Items]	'	'
Options Outstanding	342,500	410,000
Options Outstanding, Weighted Average Exercise Price Per Share	$5.85	$5.85
Options Outstanding, Weighted Average Remaining Contractual Term (Years)	'211 days	'
Options Outstanding, Aggregate Intrinsic Value	222,625	'
Options exercised	-67,500	'
Options exercised, Weighted Average Exercise Price Per Share	$5.85	'
Options exercisable	342,500	'
Options exercisable, Weighted Average Exercise Price Per Share	$5.85	'
Options exercisable, Weighted Average Remaining Contractual Term (Years)	'211 days	'
Options exercisable, Aggregate Intrinsic Value	$222,625	'

Note_12_Income_Taxes_Details

Note 12 - Income Taxes (Details) (USD $)	3 Months Ended			9 Months Ended
	Sep. 30, 2014	Mar. 31, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Note 12 - Income Taxes (Details) [Line Items]	'	'	'	'	'
Income Tax Expense (Benefit)	$2,324,000	($1,308,000)	($2,825,000)	$5,410,000	$2,641,000
Liability for Uncertain Tax Positions, Noncurrent	969,000	'	'	969,000	'
Liability for Uncertain Tax Positions, Current	969,000	'	'	969,000	'
Increase (Decrease) in Income Taxes	-2,000	'	'	290,000	'
Foreign Jurisdictions [Member]	'	'	'	'	'
Note 12 - Income Taxes (Details) [Line Items]	'	'	'	'	'
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$517,000	'	'	'	'

Note_13_Segment_Reporting_Deta

Note 13 - Segment Reporting (Details) - Financial Information by Reportable Geographic Segment (USD $)	3 Months Ended				9 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Mar. 31, 2014	Sep. 30, 2013	Mar. 31, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'
Research and development revenue	$1,797	'	$2,027	'	$5,281	$16,288	'	'
Product royalty revenue	16,811	'	13,595	'	44,200	37,271	'	'
Product sales revenue	11,717	'	5,378	'	25,572	10,994	'	'
Co-promotion revenue	936	'	'	'	2,021	61	'	'
Contract and collaboration revenue	202	'	163	'	619	490	'	'
Total revenues	31,463	'	21,163	'	77,693	65,104	'	'
Cost of goods sold	4,974	'	6,267	'	12,163	9,457	'	'
	5,631	'	'	'	5,631	'	'	'
Research and development expenses	5,297	'	4,474	'	14,684	14,528	'	'
Depreciation and amortization	263	'	364	'	984	1,117	'	'
Other operating expenses	11,655	'	11,102	'	34,048	33,485	'	'
Income (loss) from operations	3,643	'	-1,044	'	10,183	6,517	'	'
Interest income	26	'	20	'	106	63	'	'
Interest expense	-384	'	-461	'	-1,176	-1,449	'	'
Other non-operating expense, net	519	-199	183	1,150	143	2,203	3,517	1,827
Income (loss) before income taxes	3,804	2,063	-1,302	-1,934	9,256	7,334	10,943	7,977
Capital expenditures	13	'	13	'	62	153	'	'
Americas [Member]	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'
Research and development revenue	1,797	'	2,027	'	5,281	16,288	'	'
Product royalty revenue	16,811	'	13,595	'	44,200	37,271	'	'
Product sales revenue	170	'	170	'	551	277	'	'
Co-promotion revenue	936	'	'	'	2,021	61	'	'
Contract and collaboration revenue	141	'	141	'	424	424	'	'
Total revenues	19,855	'	15,933	'	52,477	54,321	'	'
Cost of goods sold	79	'	3,389	'	375	3,465	'	'
	1,502	'	'	'	1,502	'	'	'
Research and development expenses	2,733	'	3,860	'	7,565	6,446	'	'
Depreciation and amortization	140	'	309	'	514	543	'	'
Other operating expenses	8,626	'	8,893	'	25,306	27,368	'	'
Income (loss) from operations	6,775	'	-518	'	17,215	16,499	'	'
Interest income	24	'	18	'	67	54	'	'
Interest expense	-343	'	'	'	-1,054	'	'	'
Other non-operating expense, net	29	'	6	'	31	-9	'	'
Income (loss) before income taxes	6,485	'	-494	'	16,259	16,544	'	'
Capital expenditures	13	'	9	'	58	40	'	'
Europe [Member]	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'
Product sales revenue	142	'	17	'	297	37	'	'
Contract and collaboration revenue	51	'	12	'	165	34	'	'
Total revenues	193	'	29	'	462	71	'	'
Cost of goods sold	318	'	4	'	357	12	'	'
	4,129	'	'	'	4,129	'	'	'
Research and development expenses	1,893	'	-305	'	4,528	4,307	'	'
Depreciation and amortization	116	'	47	'	448	548	'	'
Other operating expenses	2,630	'	1,646	'	7,364	3,374	'	'
Income (loss) from operations	-8,893	'	-1,363	'	-16,364	-8,170	'	'
Interest income	2	'	2	'	6	8	'	'
Interest expense	'	'	-417	'	'	-1,326	'	'
Other non-operating expense, net	-443	'	95	'	547	-169	'	'
Income (loss) before income taxes	-9,334	'	-1,683	'	-15,811	-9,657	'	'
Capital expenditures	'	'	4	'	2	110	'	'
Asia [Member]	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'
Product sales revenue	11,405	'	5,191	'	24,724	10,680	'	'
Contract and collaboration revenue	10	'	10	'	30	32	'	'
Total revenues	11,415	'	5,201	'	24,754	10,712	'	'
Cost of goods sold	4,577	'	2,874	'	11,431	5,980	'	'
Research and development expenses	671	'	919	'	2,591	3,775	'	'
Depreciation and amortization	7	'	8	'	22	26	'	'
Other operating expenses	399	'	563	'	1,378	2,743	'	'
Income (loss) from operations	5,761	'	837	'	9,332	-1,812	'	'
Interest income	'	'	'	'	33	1	'	'
Interest expense	-41	'	-44	'	-122	-123	'	'
Other non-operating expense, net	933	'	82	'	-435	2,381	'	'
Income (loss) before income taxes	6,653	'	875	'	8,808	447	'	'
Capital expenditures	'	'	'	'	$2	$3	'	'

Note_14_Subsequent_Events_Deta

Note 14 - Subsequent Events (Details) (Subsequent Event [Member], Global License Agreement [Member], USD $)	Oct. 17, 2014
In Millions, unless otherwise specified
Takeda [Member]	'
Note 14 - Subsequent Events (Details) [Line Items]	'
Contract Receivable	$14
Research and Development Arrangement [Member] | Takeda [Member]	'
Note 14 - Subsequent Events (Details) [Line Items]	'
Contractual Obligation	6
Maximum [Member] | Takeda [Member]	'
Note 14 - Subsequent Events (Details) [Line Items]	'
Revenue Recognition, Milestone Method, Revenue Potential	$35